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Introduction 
 
preparation – fun – friends – alcohol – music – crowd – electronic dance – 
festival – tunnel – heat – narrows – euphoria – bottleneck – stumble – 
orientation – fall down – breathlessness – screams – way out – fear – injured 
people – escape – dead people – panic – crowd rush – 500 injured people 
(physical) – 12 people dead –  one year later – ? injured people 
(psychologically) 
 
1.1 Psychiatric disorders - anxiety disorders  
To this day, triggers for psychiatric disorders are often unknown and the 
underlying physiological changes are poorly understood. Probably because of 
this fact, the bigger part of the general public (Western Europe) does not 
consider psychiatric disorders as serious diseases, and indeed, it is hard to 
comprehend why people are scared of facing spiders. However, anxiety 
disorders are widely spread with a prevalence of Europe is about 50% (Olesen, 
2003; Sobocki et al., 2005), and almost everybody, directly or indirectly, is 
confronted with these affective diseases.  
As recently as one year ago (2010), a crowd rush during the Love Parade in 
Duisburg, Germany led to injuries and death of people. Sadly enough, the 
tragedy was not over after a few days, it is still lasting. To this day, many of the 
people involved have to deal with nightmares, problems in concentrating, lack of 
motivation, emotional blunting and social withdrawal, or even the incapability of 
handling their everyday life. 
 
They came down with a post-traumatic stress disorder (PTSD).  
 
 
 
Introduction 
 
4 
1.2 Post-traumatic stress disorder (PTSD) 
PTSD was first defined by A. Kardiner in 1941 and called physioneurosis in 
which patients developed an enduring vigilance for and sensitivity to 
environmental threat. “These patients cannot stand being slapped on the back 
abruptly; they cannot tolerate a misstep or stumble. From a physiological point 
of view, a state of readiness for fright reactions” (p 95).  
PTSD, as characterized in the Diagnostic and Statistical Manual for Psychiatric 
Disorders1 (DSM IV), implies a traumatic (life-threatening) event (criterion A), 
which after an incubation time leads to three main clusters of symptoms. First, 
maintained trauma related memories (criterion B) including distressing 
recollections and dreams about the event, flashbacks, psychological distress 
with and physiological reactions to reminders of the event – patients simply can 
not stop thinking about the event. Second, emotional numbing and avoidance of 
trauma-related stimuli (criterion C) including the effort to avoid thoughts, 
feelings, or conversations as well as activities, places, or people associated with 
the event and diminished interest in significant activities. And third, 
hyperarousal (criterion D) including difficulties in falling or staying asleep as well 
as in concentrating, hypervigilance, and exaggerated startle response. For 
diagnose of PTSD, these three clusters of symptoms have to persist over one 
month (criterion E) and disturb functioning of everyday life performance. The 
life-time prevalence of experiencing a traumatic event is as high as 56%, but 
only 15% of confronted people develop PTSD over time and one third of these 
still show symptoms ten years after the traumatic event (Kessler et al., 1995). 
These data and the mentioned symptoms enforce the necessity for a specific 
therapy of PTSD which has not been identified yet.  
Current therapies mostly target single symptoms, come along with side effects, 
and frequently lead to a relapse after the end of the treatment. Therefore, they 
are not satisfying options. To enhance therapeutic efficiency and the 
                                            
 
1
 DSM IV: the current classification of anxiety disorders includes generalized anxiety (GAD), 
phobias, and post-traumatic stress disorders (PTSD), as well as panic and obsessive 
compulsive disorders (Washington, DC, American Psychiatric Association, 2000) 
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compliance of PTSD patients, a better understanding of the disease is 
indispensable. According to McKinney (McKinney, 1984), animal models are 
‘experimental preparations developed in one species for the purpose of 
studying phenomena occurring in another species. In the case of animal models 
in human psychopathology, one seeks to develop syndromes in animals which 
resemble those of humans in certain ways in order to study selected aspects of 
human psychopathology.’ A promising animal model for psychiatric disorders 
has to include three validation criteria: First, the face validity which includes the 
parallelism in behavioral responses of the animal to the symptoms obtained in 
humans. Second, the construct validity which requires similar neurological 
changes in the animal model as compared to the human situation. And third, the 
predictive validity which supposes a therapeutic effect of clinically effective 
drugs also in the animal model. 
 
1.3 Animal model of PTSD 
For most traumata used for the induction of PTSD-like symptoms in animal 
models, including physical restraint, underwater-holding, predator confrontation, 
social confrontations, and learned-helplessness (Table 1), the intensity of the 
trauma can only be increased by prolongation or repetition (onset of 
habituation) (Adamec and Shallow, 1993; Richter-Levin, 1998; Cohen et al., 
2000). In contrast, using a single electric foot shock as the traumatic event, 
trauma intensity can be modified by increasing the electrical current without 
prolongation or repetition of the traumatic event. 
Furthermore, abnormal psychophysiological reactions in PTSD occur on two 
different levels. First, in response to specific reminders of a trauma and second, 
in response to unspecific stimuli, such as loud noises, indicating a loss of stimuli 
discrimination (van der Kolk, 2001).  
In
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Time line 
d0: 2 h immobilization; d1+3+7 EPM (rats) 
d0: 1.5 mA/ 2 s foot shock; d28: contextual fear (mice) 
d0: 2 mA/ 2 s foot shock ; d1/ 21/ 42 locomotion + EPM (mice) 
d0: 40* 2 mA/ 200 ms tail shock; d4+7+10 ASR (rats) 
d0-9: 5-10 min soc. defeat stress; d10: social interaction (mice) 
d0: <7 min social defeat stress; 24 h/ 4 weeks social interaction (mice) 
d0: 30 s underwater; 20 min water maze (rats) 
d0: 30 s underwater (rats) 
d0: 30 s underwater; 1 h: EPM + water maze (rats) 
d0: 5 min cat exposure; d1, 2, 7, 14, or 21: plus maze + hole board (rats) 
d0: 5 min cat exposure; d7: hole board + EPM (rats) 
d0: 5 min cat exposure; d7 EPM (rats) 
 
d0: inescapable tail shocks (rats; review) 
d0: 200 tail shocks in 40 min (0.8 mA; 5-15 s;); d1: LH behavior 
References 
Belda et al., 2008 
Siegmund and Wotjak, 2006 
Pynoos et al., 1996 
Servatius et al., 1995 
Golden et al., 2011 
Trainor et al., 2011  
Wang et al., 2000  
Cohen et al., 2007 
Richter-Levin, 1998 
Adamec and Shallow, 1993 
Adamec et al., 1998 
Cohen et al., 2003 
Hammak et al., 2011 
Mallei et al., 2011 
Stressor 
physical restraint 
inescapable electric shock 
social confrontations 
underwater-holding 
exposure to a predator 
learned-helplessness 
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Therefore, associative fear memories and non-associative fear sensitization 
seem to play an important role in the development and maintenance of PTSD 
(Foa et al., 1992; Charney et al., 1993; Sorg and Kalivas, 1993), but only a few 
animal models reflect that criterion (Siegmund and Wotjak, 2006, 2007). 
Associative and non-associative memories 
The basis of associative learning is the classical conditioning paradigm, first 
described by the experiments performed by Ivan Pavlov around 1900 (Gantt, 
1927). Pavlov signalled his dog the occurrence of food (unconditioned stimulus, 
US) by ringing a bell (neutral stimulus, NS). After learning this link, the dog 
started to salivate in appearance of the acoustic cue of the bell only. So, the 
neutral stimulus became a conditioned stimulus (CS).  
In relation to PTSD, traumatic memories and flashbacks that occur in response 
to a trauma cue (directly related to the trauma) are based on such associative 
memories (Costanzi et al., 2011). Before the traumatic event, these stimuli (the 
bell) are neutral – without any (negative) association – but in combination with 
the trauma, they become conditioned stimuli and therefore are able to evoke the 
reaction to the trauma by themselves. 
On the other hand, habituation and sensitization are two examples for non-
associative memories. Habituation is a progressive and implicit diminution of a 
behavioral response upon repeated stimulus presentation. After the first contact 
with a stimulus, the animal reflects subconsciously if the response was 
adequate (reward) or not (harmful or marginal). If the response was not 
adequate, it is reduced in a stepwise manner. Sensitization, in contrast, is a 
progressive amplification of a behavioral response following repeated 
administrations of a stimulus (Bell et al., 1995). If the response to the first 
stimulus seems to be adequate (meaningful), the animal will enhance the 
consequent response. However, sensitization also reflects an increased 
response to a stimulus due to a changed general situation. For example in 
humans the startle response increases in the darkness, whereas rats, which are 
crepuscular, show higher startle responses in light (Steiner et al., 2011). 
Introduction 
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1.3.1 Face validity 
Siegmund and Wotjak (2007) established an animal model of PTSD, where 
mice receive an inescapable electric foot shock as the traumatic event and are 
tested for conditioned and sensitized fear, light/dark test, social interaction test, 
forced swim test, and modified holeboard test. Due to these results, mice 
develop exaggerated fear responses, generalization of fear, and increased 
depression-like behavior after a period of at least 28 days of fear incubation. 
Furthermore, mice show avoidance behavior in the conditioned odor avoidance 
test (Pamplona et al., 2011), as well as decreased generalized and contextual 
fear after extinction training (Golub et al., 2009). 
Most of these behavioral changes occurring in PTSD patients as well as in 
shock-traumatized mice can be detected by simple observation (analysis of the 
behavior), but rely on a physiological background, which is essential to be 
investigated. 
1.3.2 Construct validity 
Investigation of anxiety disorders assumes that animals not only show “normal” 
anxiety but psychopathological (elevated) anxiety and that animal models have 
construct validity (the biological background of psychological disorders), a 
prerequisite for studying the neurobiology and therapeutic mechanisms of 
pathological anxiety (Sartori et al., 2011). 
Changes in the neuronal activity of the brain can be assigned to either phasic or 
tonic activity changes. Phasic activity changes include modifications in 
immediate early genes (IEG) expression, like for example c-Fos expression 
(Plendl and Wotjak, 2010; Lim et al., 2011) or accumulation of 2-Deoxy-D-
glucose (2-DG2) (McCasland, 1997). These phasic changes can be employed 
best for the monitoring of activity changes in animal models of panic attacks or 
specific phobias, which are short-lasting. In contrast, tonic activity is 
hypothesized to reflect psychopathology in animal models of depression or 
                                            
 
2
 2-DG is a glucose derivative which has the 2-hydroxyl group replaced by hydrogen. This 
modificaiton prevents further glycolysis. 2-DG is trapped into the cells and therefore a good 
marker for tissue glucose use, if radioactivity labelled with 14C. 
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PTSD. Such changes are visualized e.g. by changes in cytochrome c oxidase 
activity (CO3), the magnetic resonance imaging (MRI) (Tavanti et al., 2011), the 
manganese enhanced MRI (MEMRI4), in kinases (Dahlhoff et al., 2010), in 
GluR15 (Lin et al., 2011, Thoeringer et al., submitted), decreased serotonin (5-
HT) levels in the central nervous system (Valzelli, 1982), or even the 
hippocampal volume (Golub et al., 2011). 
For mapping regional functional activity in the brain, cytochrome c oxidase (CO) 
can be used as an endogenous marker of local tissue metabolic capacity 
(Wong-Riley, 1989; Gonzalez-Lima and Garrosa, 1991). 
Cytochrome c oxidase (CO) 
CO activity is directly linked to mitochondria which are organelles found in 
eukaryotic cells. Mitochondria are just called the cellular power plants because 
of the generation of adenosine triphosphate (ATP), the main energy source in 
cells (Chance, 1961). Furthermore, mitochondria are also responsible for cell 
differentiation, cell growth, cycle, and death, and cell signaling. The functionality 
of the ATP synthase (producing ATP) is based on an electrochemical gradient, 
consisting of protons, which is generated by the electron transport chain 
(Wikstroem and Saari, 1977). This chain, consisting of 4 respiratory chain 
complexes (complex I-IV), transports protons (H+) in a series of redox (reduction 
                                            
 
3
 CO ≠ COX: cyclooxygenase (COX) is an enzyme which is responsible for formation of 
prostanoids. Pharmacological inhibition of COX is used in inflammation and pain therapy (COX 
inhibitors). 
CO ≠ CO2: carbon dioxide (CO2) is a physiological transmitter involved in the autoregulation of 
blood supply and the regulation of blood pH (, if converting into HCO3
-
  by carbonic anhydrase in 
the red blood cells). 
CO ≠ CC: cytochrome c (CC) is a small heme protein which is an essential component of the 
electronic transport chain, where it carries one electron. CC is oxidized by CO. 
4
 MEMRI: Manganese ions are paramagnetic and therefore shorten the T1-times of the 
surrounding tissue. Based on the fact, that neuronal activity increases the Ca
2+
 influx into the 
cell and that Ca
2+
 is quite similar to Mn
2+
 (manganese), neuronal activity also increases Mn
2+
 
influx into the cell and therefore images areas with high neuronal activity. As a result, Mn
2+
 
enhances MRI. 
5
 GluR1 is a subunit of Ca
2+
-permeable AMPARs (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors). 
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and oxidation) reactions across the membrane to the intermembrane space 
(Figure 1) (Alberts et al., 1995). 
The enzyme cytochrome c oxidase (CO) or complex IV, the last mitochondrial 
respiratory chain complex, is a large transmembrane protein complex including 
two atoms of each copper and iron, consuming over 90% of the oxygen (Mahad 
et al., 2009). It receives an electron from each of 4 cytochrome c (CC) 
molecules which are reduced from CC(Fe2+) to CC(Fe3+) and transfers the 
electrons to one oxygen molecule (O2), thereby oxidizing molecular oxygen to 
two molecules of water (H2O) (Figure 2). 
 
Intermembrane space
Matrix
Outer membrane
Inner membrane
ATP synthase
IV
III
I
H+
H+
H+
CC
ADP+P
ATP
H+
NADH
NAD+H+
O2 H2O
Succinate
Fumarate
Q
II
Q
 
Figure 1: Schematic overview over the electron transport chain in the mitochondrion 
including the 4 respiratory chain complexes and the ATP synthase. I-IV respiratory chain 
complex I-IV, CC cytochrome c, H
+
 proton, NAD
+
 oxidized nicotinamide adenine dinucleotide, 
NAHD reduced nicotinamide adenine dinucleotide, Q quinone pool 
 
 
4 CCox (Fe
2+) + O2 + 8 H
+
in → 4 CCred (Fe
3+) + 2 H2O + 4 H
+
out 
 
Figure 2: Chemical equation of CO. CCox (Fe
2+
): oxidized cytochrome c including an ion of 
ferrum with the oxidation state of 2; CCred (Fe
3+
): reduced cytochrome c including an ion of 
ferrum with the oxidation state of 3 
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Furthermore, CO binds four protons (H+) from the inner aqueous phase to 
create water, and in addition translocates four protons (H+) across the 
membrane, thus establishing a transmembrane difference of proton 
electrochemical potential that the ATP (adenosine-tri-phosphat) synthase6 
subsequently uses to synthesize ATP7 (Wikstroem, 1981; Alberts et al., 1995). 
In 1979, Wong-Riley demonstrated the changes in the visual system of 
monocularly sutured cats with cytochrome oxidase histochemistry (Wong-Riley, 
1979). Wong-Riley and Gonzalez-Limas groups evaluated the cytochrome c 
staining for other applications, e.g. in a genetic model of helpless behavior or 
the activity in the auditory system (Hevner and Wong-Riley, 1989; Wong-Riley, 
1989; Hevner and Wong-Riley, 1990; Gonzalez-Lima and Garrosa, 1991; 
Hevner et al., 1993; Gonzalez-Lima and Cada, 1994; Poremba and Jones, 
1998; Shumake et al., 2002). 
In summary, CO is a marker for the sustained neuronal activity and might help 
to detect brain regions which are altered as a consequence of the traumatic 
event. Furthermore, CO could provide a physiological correlation to the obvious 
behavioral changes and therefore as a marker for treatment success. 
1.3.3 Predictive validity 
The treatment of PTSD has several specific goals: to reduce the severity of 
symptoms, to prevent and/or treat comorbid disorders, to decrease functional 
impairment, to modify pathogenic fear schemas, to prevent relapse, to build 
resilience, and to improve the quality of life (Ursano et al., 2007). 
Keeping in mind the timeline of PTSD, i.e. the incubation time after the trauma 
and the maintenance period in which PTSD symptoms are fully developed, the 
therapy of PTSD normally starts months or even years after the trauma 
(therapeutic therapy). However, there are several preclinical studies which 
demonstrate that pharmacological intervention in the early aftermath of a 
                                            
 
6
 ATP synthase transfers energies from H
+
 (following the electrochemical gradient via the inner 
membrane – energy are released) to phosphorylate ADP (adenosine-di-phosphat) to ATP 
(energy are needed). 
7
 ATP can provide energy within cells for metabolism. ATP → ADP + P
+
. 
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trauma (before PTSD symptoms developed; preventive therapy) have a higher 
efficiency as at later time points. For example, Cohen and colleagues showed 
that rats treated with high-dose corticosterone immediately after the trauma 
reduced behavioral disruption 30 days later (Cohen et al., 2008), and 
Thoeringer and colleagues showed in a mouse model of PTSD that the 
treatment with a CRHR18 antagonist in the first week after the trauma 
attenuated the consolidation of remote fear memories (Thoeringer et al., 
submitted). Furthermore, the efficiency of exposure therapy crucially depends 
on the timing of the intervention; earlier sessions appeared to be more effective 
than sessions performed at a later time point (Campfield and Hills, 2001). In 
addition, propranolol, a beta-blocker, administered immediately after the 
traumatic event, reduced or perhaps even prevented the development of PTSD 
in humans (Vaiva, 2003; Henry and Fishman, 2007; McGhee et al., 2009).  
However, in humans, the therapy of PTSD is, not only because of the high 
relapse rate after the end of treatment, still unsatisfying. 
Nevertheless, a huge line-up of different active agents exists (Box 1) and are 
combined in a meta-analysis of social anxiety disorders (de Menezes et al., 
2011). First-line pharmacological treatment of PTSD are selective serotonin 
reuptake inhibitors (SSRI) including sertaline, paroxetine9, fluoxetine10, 
fluovoxamine, citalopram, and escitalopram (Asnis et al., 2004; Schoenfeld et 
al., 2004; Ravindran and Stein, 2009). Furthermore, selective norepinephrine 
(NE) reuptake inhibitors (SNRIs, including duloxetine, venlafaxine, 
desvenlafaxine, and milnacipran), tricyclic antidepressants (TCAs) and 
monoamine oxidase inhibitors (MAOIs), other antidepressants (burpropion SR -
selective NE and dopamine reuptake inhibitor), among anti-adrenergic agents, 
anticonvulsants, benzodiazepines, and others are second- or third-line 
treatments of PTSD (Ravindran and Stein, 2009).  
                                            
 
8
 CRHR1: corticotropin-releasing hormone (CRH) receptor 1 
9
 sertaline and paroxetine: indication for PTSD in Germany (FDA approval) 
10
 fluoxetine: indication for PTSD in U.S.A., in Germany only for depression (not PTSD) 
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As fluoxetine (a SSRI) is the first-line treatment in PTSD patients, to ensure 
predictive validity, fluoxetine was used in the present study. 
 
Box 1: Overview of pharmacological agents clinically used for PTSD 
SSRIs
- fluoxetine
- sertaline
- paroxetine
- fluovoxamine
- citalopram
- escitalopam
SNRIs
- ducloxetine
- venlafaxine
- desvenlafaxine
- milnacipran
MAOIs
- phenelzine
- brofaromine
Tricyclic antidepressants
- desipramine
- amitriptyline
- imipramine
Other antidepressants
Anti-adrenergic agents
Anticonvulsants
Benzodiazepines
 
 
Fluoxetine (SSRIs) 
Based on the good compliance of fluoxetine treatment, it is the mostly used 
anti-depressive drug worldwide. Fluoxetine is also indicated of generalized fear 
and panic disorders. Furthermore, several studies showed an improvement of 
PTSD symptoms under fluoxetine treatment (van der Kolk et al., 1994; Connor 
et al., 1999; Martenyi et al., 2002). 
Nevertheless, patients are prone for relapse of symptoms upon discontinuation 
of treatment. This relapse urges for a refinement of pharmacologic interventions 
and the identification of markers for treatment success. 
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1.4 Aims 
The aim of this work was the identification of new approaches for the PTSD 
therapy and/or the sophistication of already existing therapies via mimicking the 
symptomatology observed in humans using a mouse model of PTSD. 
Additionally, a potential marker of treatment success was to be revealed. 
Our working hypotheses were as follows: 
  
(1) A traumatic event (a single electric foot shock) changes the tonic activity 
(cytochrome c oxidase) in the brain one month after the trauma. 
 
(2) Chronic treatment with fluoxetine starting either right after the trauma 
(preventive treatment) or 28 days later (therapeutic treatment) prevents or 
reverses the PTSD-like symptoms. 
 
(3) Chronic treatment with fluoxetine starting either right after the trauma 
(preventive treatment) or 28 days later (therapeutic treatment) reverses the 
changes in CO activity. 
 
(4) The discontinuation of treatment with fluoxetine after preventive or 
therapeutic treatment, leads to a relapse of PTSD-like symptoms. 
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1.5 Experimental overview 
The experimental schedules of all experiments are summarized in Figure 3. 
Experiment 1: Searching for construct validity in long-lasting changes in 
cellular activity in the brain, CO activity was analysed in shocked compared to 
non-shocked mice. Mice were shocked or non-shocked (control) at day 0 (d0). 
They remained in their home cages until day 28 (d28) post shock, when they 
were tested for hyperarousal (d28), generalized and contextual fear (d29-30), 
and avoidance (d32-33). After an additional week, brains were collected and 
CO staining was performed. 
Experiment 2: To confirm the CO data of experiment 1 and to test for the 
influence of incubation time after the trauma, mice were shocked or non-
shocked (control) at d0 and tested for hyperarousal at d2 or d28. After an 
additional week, brains were collected and CO staining was performed. 
Experiment 3: To investigate whether the increase in CO (Exp. 1 and 2) activity 
involves changes in AMPAR or GABAAR neurotransmission, in vitro patch-
clamp recordings of AMPAR-mEPSPs and GABAAR-mIPSCs in the dentate 
gyrus (DG) and the cornus ammonis 1 (CA1) were performed. 
Experiment 4: To confirm the changes in AMPAR neurotransmission in the DG 
(Exp. 3), the physiological relevance of hippocampal GluR1 (subunit of AMPAR) 
for remote contextual fear memories was investigated. For equal levels of 
sensitization between different groups, mice were stratified at d1 or d27. At d3 
or d29, mice were injected with philanthotoxin 433 (PhTX, 100µM 
intrahippocampal), a specific blocker of Ca2+-permeable GluR1 containing 
AMPARs and tested for contextual fear 30 minutes later. 
Experiment 5: To assess whether pharmacological treatment influences the 
PTSD-like symptoms and/or the CO activity (Exp. 1 and 2), mice were shocked 
or non-shocked (control) at d0 and treated either from d1 until d42 (preventive) 
or from d28 until d65 (therapeutic) with fluoxetine (20 mg/kg/d) or vehicle via 
drinking water and tested under treatment for hyperarousal and generalized and 
contextual fear. After an additional week, brains were collected and CO staining 
was performed. 
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Experiment 6: To control, whether long-lasting changes in CO activity (Exp. 5) 
predict relapse of PTSD-like symptoms, behavioral tests were performed after 4 
weeks of wash-out period. Mice were shocked or non-shocked (control) at d0, 
remained in their home cages, and received fluoxetine (20 mg/kg/d) or vehicle 
via drinking water from d1-28 (preventive) or d28-56 (therapeutic). At d28, the 
preventively treated mice were tested for the presence of PTSD-like symptoms 
and for successful fluoxetine treatment (1’ tone). The therapeutically treated 
mice were tested at d28 for the presence of PTSD-like symptoms and for 
stratification, and at d56 for successful fluoxetine treatment (1’ tone). Four 
weeks after the end of treatment, mice were tested for hyperarousal and 
generalized and contextual fear. 

d0 d2 d28
7↓ &O
↓ CO
↓ CO
FLUOXETINE♪ T   CO↓64
1
2
4
5
3
6
48
42
42
FLUOXETINE♪ T♪64
FLUOXETINE T    CO↓64
FLUOXETINE ♪ T 64
d27d-14 d0 d1 d29d3
Philanthotoxin
♪OP30
♪OP30
number of 
animalsExp.
mIPSCs
d0 d28
12
mIPSCs12 DG
CA1
d0 d2 d28 d56 d84
mEPSCs12 DG
mEPSCs12 CA1
 
Figure 3: Experimental overview. CO cytochrome c oxidase; T: tested for PTSD-like 
symptoms (hyperarousal (ASR), generalized and contextual fear (cylinder/tone, hexagon, and 
chamber), and/or avoidance); OP surgery; ↓ collection of brains;      Injection; ♪ Stratification. 
For further details see Figure 4.  
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Material and Methods 
1.6 Animals 
All experimental procedures were approved by the Committee on Animal Health 
and Care of the State of Upper Bavaria (Regierung von Oberbayern) and 
performed in strict compliance with the European Union recommendations for 
the case and use of laboratory animals (86/609/CEE).  
A total number of 496 mice (plus additional 120 mice for the standards of the 
cytochrome c oxidase staining) were used. All experiments were performed with 
male C57BL/6NCrl mice11 which were purchased from Charles River Germany 
at the age of 6 to 7 weeks.  
Mice were singled housed and kept under standard housing conditions12 in the 
animal facility of the Max Planck Institute of Psychiatry for at least 2 weeks 
before the start of the experiments or surgery and remained under these 
conditions until the end of the experiments. Mice were tested in the dark phase 
between 10:00 am and 7:00 pm. Sample sizes are indicated in the respective 
description of the experiments (Figure 3). 
 
1.7 Surgery 
Mice were initially anesthetized with isoflurane (Forene®, Abbott, Germany) and 
placed in a stereotaxic apparatus (TSE systems, Germany) where they received 
a sustentative inhalation anesthesia with isoflurane. Before opening the skull, 
mice received analgesic treatment (0.5 mg/kg meloxicam s.c., Metacam®, 
Boehringer Ingelheim, Germany), afterwards stereotactically guided holes were 
drilled and guide cannulae (23G) were implanted bilaterally above the dorsal 
                                            
 
11 The “PTSD vulnerable” mouse strain (Siegmund and Wotjak., 2007; Siegmund et al., 2009; 
Dahlhoff et al., 2010). 
12 Standard housing conditions: Makrolon type II cage with wood shavings and nesting 
material, 12:12 hours light dark schedule, lights off at 9:00 am, 22 ± 2°C room temperature, and 
55 ± 5% humidity, free access to food and water. 
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hippocampus. Coordinates based on the stereotaxic mouse brain atlas (Franklin 
and Paxinos, 2001) were -1.8 mm posterior, ±1.3 mm lateral to bregma, and 
1.0 mm below the surface of the skull. Cannulae were fixed to the skull with 
dental cement (Paladur®, Heraeus, Germany). Analgesic treatment was 
continued for 3 days via drinking water (0.5 mg/kg/d meloxicam). Before starting 
the experiment, mice were allowed to recover from surgery for 2 weeks. Correct 
positions of coordinates were controlled post mortem by histological 
examination of cryo sections, stained with cresyl violet. Mice were excluded 
from the analysis if coordinates were incorrect. 
 
1.8 Intracerebral injections 
Mice were slightly anaesthetised with isoflurane, and philanthotoxin 433 (PhTX, 
P207, Sigma-Aldrich) was infused into the hippocampus at a volume of 0.5 µl 
per injection site over the course of 1 min. Injections were performed by means 
of an injection cannula which was connected to a microliter syringe via a 
calibrated tubing containing an air bubble for monitoring volume progress. The 
injection cannula protruded from the guide cannula by 1 mm thus reaching the 
stratum lacunosum moleculare of the dorsal hippocampus. After completion of 
the injection, the cannula was left in place for another minute before removal. 
Mice were excluded from the experiment, if fluid or blood was flowing out of the 
guide cannula. 
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Figure 4: Overview over all behavioral setups used in this thesis. Gray bars show the 
analyzed part of the protocol, indicated via the symbols in the following figures. 
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1.9 Behavioral tests  
All setups and procedures have been described previously (Siegmund and 
Wotjak, 2007; Golub et al., 2009; Pamplona et al., 2011) and are shown in 
Figure 4. 
1.9.1 Shock application 
Mice were placed into a chamber (MED Associates U.S.A.) (cubic shape, metal 
grid floor, two metal and two Plexiglas walls, odor of 70% ethanol), and after 
198 s they received an inescapable electric foot shock (1.5 mA current intensity/ 
2 s duration) via the metal grid at the floor. The electric foot shock constituted 
the traumatic event for the mice. After receiving the shock, mice remained in the 
shock context for another 60 s before being placed back to the home cage. 
Non-shocked mice underwent same procedure, but without the foot shock. 
1.9.2 Stratification 
To ensure equal levels of sensitisation between different groups (before the 
treatment or to control for the development of PTSD-like symptoms or the 
treatment effect), sensitized fear was measured essentially as the response to 
neutral tone in the cylinder (cylindrical shape, bedding on the floor, transparent 
and smooth Plexiglas wall, odor: 1% acetic acid). To avoid associations with the 
sensitized chamber, the odor was different in all environments (cylinder, 
hexagon, chamber, startle set up, CODA). After 180 s, a neutral tone (80 dB, 
9 kHz) was presented for 60 s. After the tone, mice remained in the cylinder for 
another 60 s before placed back in their home cages. 
1.9.3 Acoustic startle response - ASR 
To measure hyperarousal symptomatology, mice were tested for acoustic 
startle responses (ASR). Therefore, mice were placed into a non-restrictive 
Plexiglas cylinder (inner diameter 4 cm, length 8 cm) mounted onto a plastic 
platform and placed in a sound attenuated chamber (SR-LAB, San Diego 
Instruments SDI, San Diego, CA, USA). The movement was detected by a 
piezoelectric element mounted under each platform and the voltage output of 
the piezo was amplified and digitized (sampling rate 1 kHz) by a computer 
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interface (I/O-board provided by SDI). The startle amplitude was defined as the 
peak voltage output within the first 50 ms after stimulus onset and quantified by 
means of SR-LAB software. Startle stimuli and background noise were 
delivered through a high-frequency speaker. Four different startle stimuli 
consisting of white noise bursts, 20 ms duration, and 75, 90, 105, or 115 dB 
intensity (INT) were presented in a constant background noise of 50 dB. Within 
control trials only background noise was present. After an acclimation period of 
5 min, 10 control trials and 80 startle stimuli (20 stimuli each intensity) were 
presented in a pseudorandom order. After each session, Plexiglas cylinders 
were cleaned with soap water and dried. 
1.9.4 Generalized and contextual fear 
To measure generalized fear, mice were placed in the cylinder (as described for 
the stratification). After 180 s, a neutral tone (80 dB, 9 kHz) was presented for 
180 s. After the tone, mice remained in the cylinder for another 60 s. 
Furthermore, animals were tested for 3 min in the hexagon (hexagonal shape, 
metal grid floor, non-transparent and rough Plexiglas walls, and odor of 
1:2000 isopentyl acetate (“banana flavor”)), including the metal grid as a 
dominant feature of the trauma context (chamber). Contextual fear was 
measured by exposing the mice to the sensitized chamber for 3 min. All 
contexts were cleaned after each trial (with the detergents used as odor in the 
according protocol) and bedding was changed. For further details see Figure 4. 
Recent fear memories were measured 2 days after the shock application, 
remote fear memories after 1 month. Freezing behavior (defined as the 
absence of movement except for breathing and the head remaining in a 
horizontal position) was analyzed as a criterion for fear (Kamprath and Wotjak, 
2004). 
The sensitization and the tests for generalized and contextual fear were 
recorded by CCD cameras (Conrad Electronics, Hirschau, Germany) and 
analyzed offline (EVENTLOG, Robert Henderson, 1986). The experimentator 
was blind to treated groups and initially trained by repeated analysis of the 
video tapes until reaching a determination coefficient r2>0.9 (Figure 5).  
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Figure 5: Evaluation of freezing analysis. Double freezing analysis of a single experiment. 
n = 45 
 
1.9.5 Conditioned odor avoidance - CODA 
To test for avoidance behavior, mice were tested in the conditioned odor 
avoidance task (CODA). CODA was conducted in a rectangular box which was 
divided into three compartments that were interconnected by small openings 
with guillotine doors. A filter paper-lined Petri dish (10 cm diameter), containing 
own home cage bedding (nest compartment, center), 70% ethanol, or 1% 
acetate (left or right compartment, counterbalanced) was placed in each 
compartment. For CODA testing, mice were placed in the nest compartment for 
5 min (habituation phase) followed by 5 min of free exploration (test phase, 
open doors). During testing, the latency until the first exit of the mouse from the 
nest compartment and the time spent in each of the compartments were 
recorded. The animals’ behavior was observed and rated online. 
1.10 Fluoxetine treatment 
Fluoxetine-ratiopharm solution (Ratiopharm GmbH, Germany) was dissolved in 
drinking water resulting in a daily dose of 20 mg/kg and was provided in light-
proof drinking bottles (home cage). In the first days of treatment, body weight 
was measured every third day. Mice showed a slight, but not significant 
decrease in body weight during the first days of treatment, but remained stable 
from day 9 on. To preclude withdrawal effects after the end of treatment 
(experiment 5 and 6), mice received only 10 mg/kg/d fluoxetine (50% of the 
treatment dose) for 4 days and afterwards the drug was completely withdrawn. 
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Figure 6: Changes in body weight under fluoxetine treatment.  
 
1.11 Molecular experiments 
For cytochrome c oxidase (CO) staining, mice have been killed by an overdose 
of isoflurane. Brains were quickly removed, frozen in chilled methylbutane on 
dry ice, and stored at -80°C until sectioning them on a cryostat (20 µm). 
Sections were mounted on microscope slides (superfrost® plus, Thermo 
scientific, Germany) and stored at -80°C until staining. 
1.11.1 CO staining 
During the whole staining protocol, slides were moved gently (using a shaker). 
First, slides were fixed for 5 min in cold acetone (4°C), and washed afterwards 
3 times (5 min each) in 0.1 M Na+P-buffer13 (4°C).  
Slides were transferred into 37°C staining medium14 for 20 min. Staining was 
stopped by transferring the slides into 4°C 0.1 M Na+P-buffer, changing them 
2 times (5 min each) and post-fixing them for 30 min in 4% paraformaldehyde 
(PFA) at room temperature (RT). Sections were washed twice with 0.1 M Na+P-
                                            
 
13
 0.5M Na
+
P-buffer: 14.33g NaH2PO4 H2O, 85.29g Na2HPO4 2H2O per 1 l H2O bidest., pH 7.6 
14
 staining medium: 45 g sucrose, 390 mg DAB (2,6-Diacetylpyridine, D8801, Sigma- Aldrich), 
50 mg cytochrome c (C2506, Sigma-Aldrich), 150 mg ammonium nickel sulfate (A1827, Sigma-
Aldrich) per litre 0.1 M Na
+
P-buffer. Staining medium was made freshly before each staining. It 
was heated up to ≤40°C for 30 min and filtered afterwards. Preliminary tests verified that this 
was within the linear range of reaction product development. 
Material and Methods 
 
24
buffer for 5 min, dehydrated with ethanol (70%, 80%, 99%) and isopropyl 
alcohol (2 min each), and cover-slipped with histo-kit. Microscope images 
(AxioCam MR05®, Leica, Germany) were analyzed with Image J. Representive 
brain slices (left side) and the region of interest (ROI) (enhanced at the right 
side) are shown in Figure 7. 
1.11.2 Tissue homogenization 
Tissue homogenization was performed as previously described (Riddle and 
Forbes, 2005). Homogenates of mouse brain and liver were used to generate a 
standard curve of known CO activity. Tissue was cooled on ice during all 
procedures. After being minced into fine pieces with a scalpel, tissue was 
homogenized. To produce the lowest CO activity standard, the brain 
homogenate was transferred into a plastic tube and heated up to 60°C in a 
water bath for 1 h. For intermediate CO activity standards, combinations of 
brain (inactivated; 0% activity) and liver homogenates (100% activity) were 
prepared by weighting proportions of homogenates (w/w), followed by thorough 
mixing. A small measured amount (100 mg) from each of the final 6 standards 
was separated and divided into 2 ml aliquots and briefly centrifuged at 250g to 
remove air bubbles. The paste standards were frozen in 2-methylbutane cooled 
with dry ice and stored at -80°C. Sections of paste standards were cut on a 
cryostat and mounted as described below for tissue preparation. 
1.11.3 Spectrophotometric determination of CO activity 
CO activity in tissue paste homogenates was performed as described by Hess 
and Pope (1953; Hevner et al., 1993) with slight modifications. A 1% 
cytochrome solution (3 ml) was prepared in 0.05 M potassium phosphate 
buffer15, pH 7.0 (K+P-buffer). Cytochrome was reduced by addition of 40 mg 
sodium ascorbate and dialyzed in Spectropor 1 dialysis tubing (MWCO 6000- 
8000) against three changes of K+P-buffer (3 l each) for at least 24 h at 4°C. 
The recovered cytochrome solution was diluted to 0.07% in K+P-buffer and 
                                            
 
15
 0.5 M potassium phosphate buffer (K
+
P-buffer): 68 g KH2PO4, 1 l H2O bidest., pH 7.0 with 1 M 
KOH 
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checked for sufficient reduction (550/565 nm optical density (OD) ratio ≥ 6). 
Twenty percent (w/v) solutions of fresh tissue pastes in cold isolation buffer16 
were homogenized on ice using micro ground glass dounces. 
To measure CO activity, an aliquot of the 20% tissue homogenate stock was 
further diluted to 0.25% in cold isolation buffer with the addition of 0.5% sodium 
deoxycholate (Sigma-Aldrich). Homogenates were slightly vortexed, incubated 
for 8 min at room temperature (RT), vortexed again, and then placed on ice. 
Reduced cytochrome solution (1.5 ml), oxidized by the addition of saturated 
potassium ferricyanide (Sigma-Aldrich), was used to zero the 
spectrophotometer at 550 nm. Five microliters of 0.25% tissue paste standard 
homogenate were added to a 1 cm path length cuvette containing 1.5 ml of 
22°C reduced cytochrome solution. The cuvette was inverted twice to disperse 
the solubilized tissue and OD readings at 550 nm were recorded at 15 s 
intervals; starting at 30 s and finishing after 2.5 min. Measurements were made 
in triplicate for each paste standard. All reactions were linear over the initial 2.5 
min assayed. The change in ODs for the five recorded 1 min intervals (0.5 - 1.5, 
0.75 - 1.75 min, etc.) for each sample were averaged. CO activity was 
calculated by dividing the mean change in OD 550 per minute by the difference 
in the molar extinction coefficients for reduced (28 mM−1 cm−1) minus oxidized 
(8.4 mM−1 cm−1) cytochrome (19.6 mM−1 cm−1 or 19.6 mol−1 ml cm−1). This result 
was divided by 8.3×10−6 g tissue sampled per ml to give CO activity, defined as 
micromoles of reduced cytochrome substrate oxidized per minute at 22°C 
(pH 7) per gram of tissue (mol/min/g). In CO figures, CO activity is denoted in 
mol/min/g, except otherwise mentioned (relative CO activity in Experiment 1). 
Chemicals for Na+P-buffer, K+P-buffer, and isolation-buffer were purchased 
from Merck (Germany). 
                                            
 
16
 isolation buffer: 10 mM Tris-HCl, pH 7.4, containing 0.32 M sucrose and 1 mM dipotassium 
EDTA 
Material and Methods 
 
26
Cg1
PrL
IL
AcbC
AcbSh
LH
m
P
F
C
A
c
b
P
V
A
L
H
1.98
1.54
-0.34
-0.70
CO staining ROI
CPu
C
P
u
-0.34
PVA
m
P
F
C
A
c
b
P
V
A
L
H
C
P
u
 
Figure 7: 
Representative CO 
stained coronal 
slices of the region 
of interest (ROI, left 
side). The blotted 
box is enlarged on 
the right (Franklin 
and Paxinos, 2001), 
and analyzed 
regions are labeled 
(distance to Bregma 
is noted down right 
in mm). 
Acc - nucleus 
accumbens,  
AccC - accumbens 
nucleus core, 
AccSh - accumbens 
nucleus shell,  
Cg1 - cingulate cortex 
(area 1), 
CPu -  caudate 
putamen (striatum), 
IL - infralimbic cortex,  
LH - lateral 
hypothalamic area, 
mPFC - medial 
prefrontal cortex,  
PrL - prelimbic cortex,   
PVA - paraventricular 
thalamic nucleus 
(anterior) 
(to be continued on 
the next page) 
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Figure 8: Typical CO 
stained coronal 
slices of the region 
of interest (left side; 
in continuation) 
AMY - amgdala,  
BLA - basolateral 
amygdaloid nucleus,  
CA1 - cornus 
ammonis 1,  
CA1v - ventral cornus 
ammonis 1,  
CA3 - cornus 
ammonis 3,  
CA3v - ventral cornus 
ammonis 3,  
CeA - central 
amygdaloid nucleus,  
DG - dentate gyrus,  
dHPC - dorsal  
hippocampus,  
LA - lateral 
amygdaloid nucleus,  
LHb - lateral 
habenular nucleus,  
MHb - medial 
habenular nucleus,  
PAG - periaqueductal 
gray,  
PF - parafascicular 
thalamic nucleus,  
SN - substancia nigra,  
vHPC - ventral 
hippocampus 
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1.12 Electrophysiology 
1.12.1 Brain slice preparation 
Acute 350 µm thick coronal hippocampal slices were prepared using a 
vibratome (HM650V, Thermo Scientific) and maintained in artificial 
cerebrospinal fluid (aCSF17) saturated with 5% CO2 / 95% O2. Slices were 
allowed to recover in a storage chamber initially at 36°C for 30 min and for 
another 30 min at RT before being transferred to the recording chamber.  
1.12.2 AMPAR-mEPSC and GABAAR-mIPSC recordings 
Whole-cell patch-clamp recordings were carried out from granule cells of the 
dentate gyrus (DG) and the cell layer of the CA1 (cornu ammonis 1) in acute 
brain slices by means of a SEC-10LX amplifier (npi Electronics, Tamm, 
Germany). An infrared video microscope equipped with the gradient contrast 
system was used to visualize somata of DG and CA1 neurons. The pipette was 
filled with intracellular solution. Patch-clamp electrodes (open-tip resistance of 
4-6 MΩ) were pulled from borosilicate glass capillaries (Harvard Apparatus, 
Kent, UK) on a DMZ-Universal puller. Neurons were voltage-clamped at 
-60 mV, and AMPAR-mEPSCs recordings (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor miniature excitatory post-synaptic current) 
were measured while slices were continuously superfused with artificial 
cerebrospinal fluid (aCSF) containing 1 µM tetrodotoxin (TTX), 50 µM D (-)-2-
amino-5-phosphonopentanoic acid (AP5), and 10 µM (-)-bicuculline methiodide 
(BIM). For GABAAR-mIPSCs recordings (γ-aminobutyric acid receptor A - 
miniature inhibitory post-synaptic current), neurons were voltage-clamped at 
-40 mV and measured while slices were continuously superfused with 
oxygenated aCSF containing 1 µM TTX, 50 µM AP5, and 5 µM 2,3-dihydroxy-6-
                                            
 
17 aCSF (in mM): NaCl 125, KCl 2.5, NaH2PO4 1.25, CaCl2 2, MgSO4 1, NaHCO3 25, glucose 
25 at pH 7.4  
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nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX). All recordings were 
performed at RT. 
Ten minutes after breaking into the cell, AMPAR-mEPSCs or GABAAR-mIPSCs 
were recorded in individual neurons for 5 minutes. Amplitudes and frequencies 
were analyzed offline using the Mini Analysis software (Synaptosoft, GA) with a 
detection threshold set at 4 pA. 
Chemicals for aCSF preparation were purchased from Merck (Germany), TTX, 
NBQX, and AP5 from Ascent Scientific (UK), and BIM from Tocris Biosciences 
(UK). 
 
1.13 Data analysis 
Behavioral data were averaged to the testing period and presented as a 
percentage of the analysis interval. Regarding AMPAR-mEPSC or GABAA-
mIPSC recordings, mean amplitude and frequency of 5 min-recordings were 
analyzed and presented as absolute values. Statistical analysis of data was 
performed using Statistica 7 (StatSoft, USA). Graphs were created with 
GraphPad Prism 5 (GraphPad Inc., USA). Data were analyzed by unpaired 
student’s t-tests or 2-way ANOVAs when appropriate with shock and treatment 
as independent variables as indicated in the text, or repeated measures 
ANOVAs when appropriate with shock and treatment in the ASR. Newman-
Keuls post-hoc test was used for point-by-point comparisons in case of 
significant main effects. Note for the ASR-experiments: If * or # are upon the 
data points (in the figures), the interaction was significant (p≤0.05) and 
Newman-Keuls post-hoc test was used for point-by-point comparisons; if * or # 
are at the right side of the data points, the interaction was not significant and the 
significant effects (shown in the figures) were between the groups. All data are 
presented as mean ± s.e.m. Statistical significance was accepted if p≤0.05.  
For clarity and brevity, only significant and relevant results of the statistical 
analyses are reported in the main text and the figures.
Results 
 
 
30
Results 
1.14 Behavioral tests and CO activity one month after shock (Exp. 1) 
A single electric foot shock (1.5 mA/ 2 s) increased hyperarousal (Figure 8), 
generalized and contextual fear (Figure 9), and avoidance behavior (Figure 10) 
compared to non-shocked (control) mice between day 28 (d28) and day 35 
(d35).  
After the behavioral tests, mice remained in their home cages for another week 
to prevent acute influence of testing on the CO activity. 
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Figure 8: A single electric foot shock increased hyperarousal at d28 post shock (Exp. 1). 
Mice were shocked (1.5 mA/ 2 s) or non-shocked in the chamber at d0 and remained in their 
home cages for 28 days. At d28, mice were tested for hyperarousal. Acoustic startle responses 
(ASR) as a function of stimulus intensity are presented as mean ± s.e.m. Statistical analysis 
were performed by 2-way repeated measures ANOVA (F1, 42, shock=6.70, p<0.05; 
F4, 168, INT=93.87, p<0.001;F4, 168, shock*INT=7.85, p<0.001), followed by Newman-Keuls post-hoc 
test. n = 12 (non-shocked) or 32 (shocked) mice; *p<0.001 vs. non-shocked mice 
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Figure 9: A single electric foot shock increased generalized and contextual freezing 
responses at d29-30 post shock (Exp. 1). Mice were shocked (1.5 mA/ 2 s) or non-shocked in 
the chamber at d0 and remained in their home cages for 28 days. At day 28, mice were tested 
for hyperarousal symptomatology (Figure 8) and afterwards (d29-30) exposed to a neutral 
context (cylinder/ 3’ tone), the hexagon, and the sensitized chamber. The percentage of time 
mice spent in freezing behavior was analyzed. Statistical analysis were performed by unpaired 
t-test (cylinder: p<0.001, t=13.86, df=44; tone: p<0.001, t=8.090, df=44; hexagon: p<0.001, 
t=5.727, df=45, chamber p<0.001, t=12.02, df=43). n = 14-16 (non-shocked) or 29-32 (shocked) 
mice; *p<0.001 vs. non-shocked mice 
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Figure 10: A single electric foot shock increased avoidance behavior at d32-33 (Exp. 1). 
Mice were shocked (1.5 mA/ 2 s) or non-shocked in the chamber at d0 and remained in their 
home cages for 28 days. At d28 and follows, mice were tested for hyperarousal 
symptomatology (Figure 9), generalized and contextual fear responses (Figure 10), and 
afterwards for avoidance behavior. Time spent in the ethanol, acetate, and nest compartments, 
as well as the total number of entries in the ethanol and acetate compartment and the latency of 
entering the first compartment were analyzed online. Data are represented as mean ± s.e.m. 
Statistical analysis were performed by unpaired t-test (time ethanol: p=0.11, t=1.677, df=27; 
time nest: p<0.05, t=2.352, df=27; time acetate: p=0.06, t=1.943, df=27; entries ethanol: p<0.05, 
t=2.200, df=27; latency first: p=0.12, t=1.594, df=27; entries acetate: p=0.11, t=1.644, df=27). 
n = 8 (non-shocked) or 21 (shocked) mice. *p<0.05 vs. non-shocked mice 
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At day 42, cytochrome c oxidase (CO) activity was significantly increased in 
shocked compared to non-shocked mice in the following brain regions: the 
prelimbic cortex (PrL), the nucleus accumbens core (AccC) and shell (AccSh), 
the basolateral amygdaloid nucleus (BLA), the medial habenular nucleus 
(MHb), the dorsal hippocampus (CA1, CA3, DG), the ventral hippocampus 
(vCA1 and vCA3), the lateral hypothalamic area (LH), the parafascicular 
thalamic nucleus (PF), and the periaqueductal gray (PAG), but not in the 
cingulated cortex (Cg ant.), the infralimbic cortex (IL), the caudate putamen 
(CPu, striatum), the lateral (LA) and central amygdaloid nucleus (CeA), the 
lateral habenula nucleus (LHb), the paraventricular thalamic nucleus (PVA), and 
the substantia nigra (SN) (Table 2). 
 
 
PTSD-like symptoms and CO activity one month after shock 
Four weeks after the shock (traumatic event), shocked mice showed increased 
hyperarousal, generalized and contextual fear response, and avoidance 
behavior as well as increased CO activity in most of the analyzed brain regions 
(PrL, CA1+3, DG, BLA, PAG, among others) compared to non-shocked 
(control) mice. 
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Table 2: A single electric foot shock increased CO activity in most of the analyzed brain 
areas at d42 post shock (Exp. 1). Mice were shocked or non-shocked at d0 and remained in 
their home cages until d28. Between d28 and d33, mice were tested for hyperarousal, 
generalized and contextual fear responses, and avoidance behavior (Figure 8 -Figure 10). 
Afterwards, they remained in their home cages for an additional week. Brains have been 
collected at d42 and CO staining was performed.CO activity measured in relative values (not 
absolute; pilot project without standards). ns non-shocked; s shocked mice 
 CO activity (ns) CO activity (s) t, df p-value 
Prefrontal Cortex, medial 
Cg ant. 1.154 ± 0.01 n=8 1.171 ± 0.01 n=21 t=0.921 df=27 0.37 
PrL 1.136 ± 0.01 n=8 1.166 ± 0.00 n=21 t=2.975 df=27 <0.001 
IL 1.155 ± 0.01 n=8 1.169 ± 0.01 n=21 t=1.295 df=27 0.21 
Accumbens 
Acc core 1.161 ± 0.01 n=8 1.212 ± 0.01 n=21 t=3.880 df=27 <0.001 
Acc shell 1.164 ± 0.01 n=8 1.214 ± 0.01 n=21 t=3.083 df=27 <0.001 
Amygdala 
LA 1.109 ± 0.01 n=8 1.109 ± 0.00 n=21 t=0.03385 df=27 0.97 
BLA 1.151 ± 0.01 n=8 1.170 ± 0.01 n=21 t=2.623 df=27 <0.01 
CeA 1.179 ± 0.01 n=8 1.176 ± 0.01 n=21 t=0.3956 df=27 0.70 
Hippocampus, dorsal 
CA1 1.118 ± 0.01 n=8 1.143 ± 0.00 n=21 t=3.375 df=27 <0.001 
CA3 1.101 ± 0.01 n=8 1.125 ± 0.00 n=21 t=3.336 df=27 <0.001 
DG 1.288 ± 0.01 n=8 1.340 ± 0.01 n=21 t=3.390 df=27 <0.001 
Hippocampus, ventral 
CA1 1.144 ± 0.00 n=8 1.176 ± 0.00 n=21 t=3.855 df=27 <0.001 
CA3 1.142 ± 0.00 n=8 1.171 ± 0.00 n=21 t=4.078 df=27 <0.001 
Miscellaneous 
PAG 1.163 ± 0.01 n=8 1.185 ± 0.00 n=21 t=2.408 df=27 <0.05 
PVA 1.084 ± 0.01 n=8 1.098 ± 0.01 n=21 t=1.479 df=27 0.15 
LH 1.086 ± 0.01 n=8 1.110 ± 0.00 n=21 t=2.798 df=27 <0.01 
CPu 1.169 ± 0.01 n=8 1.186 ± 0.00 n=21 t=1.737 df=27 0.09 
MHb 1.131 ± 0.01 n=8 1.149 ± 0.00 n=21 t=2.462 df=27 <0.05 
LHb 1.239 ± 0.02 n=8 1.245 ± 0.01 n=21 t=0.3682 df=27 0.72 
PF 1.141 ± 0.01 n=8 1.164 ± 0.01 n=21 t=2.209 df=27 <0.05 
SN 1.187 ± 0.01 n=8 1.178 ± 0.01 n=21 t=0.6290 df=27 0.53 
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1.15 ASR and CO activity two days vs. one month after shock 
(Exp. 2) 
To verify these data (exp. 1), the behavioral data as well as the CO activity, 
experiment 1 was repeated with modifications and an analysis of changes in the 
early aftermath of the traumatic event was added.  
A single electric foot shock (1.5 mA/2 s) increased hyperarousal at d28, but not 
at d2 (Figure 11) compared to non-shocked mice. 
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Figure 11: A single electric foot shock increased hyperarousal at d28 but not at d2 
(Exp. 2). Mice were shocked (1.5 mA/ 2 s) or non-shocked in the chamber at d0 and remained 
in their home cages for 2 or 28 days before being tested for hyperarousal symptomatology. The 
difference in the ASR (to 115dB) of shocked compared to non-shocked mice (ASR = 100%) is 
represented as mean ± s.e.m. Statistical analysis were performed by unpaired t-test 
(d2: p=0.60, t=0.5260, df=38; d28: p<0.001, t=5.422, df=38). n = 16 (non-shocked) or 24 
(shocked) mice. *p<0.05 vs. non-shocked mice (data not shown) 
 
After the behavioral tests, mice remained in their home cages for another week 
to prevent acute influence of testing on the CO activity. CO activity was not 
affected at day 9 after shock (Table 3). In contrast, 35 days after the traumatic 
event, again the CO activity was increased in the following brain sections: the 
prelimbic cortex (PrL), the dorsal hippocampus (CA1+3, DG), the basolateral 
amygdaloid nucleus (BLA), and the periaque ductal gray (PAG), among others, 
(Table 4). These findings underscore the results of the first experiment. 
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ASR and CO activity two days vs. one month after shock  
At d28 but not d2 post shock mice showed increased hyperarousal compared to 
non-shocked mice. Furthermore, in shocked mice, no brain region with 
increased CO activity was found at day 9 (compared to non-shocked mice), 
whereas at day 35 the same brain regions showed an increased CO activity in 
shocked compared to non-shocked mice as at day 42 (Exp. 1). 
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Table 3: A single electric foot shock did not change CO activity in the analyzed brain 
areas at d9 post shock (Exp.2). Mice were shocked or non-shocked at d0, tested for 
hyperarousal at d2 (Figure 11), and remained in their home cages for an additional week. 
Brains have been collected at d9 and CO staining was performed. ns non-shocked, s shocked 
mice; CO activity in mol/min/g (absolute values) 
 CO activity (ns) CO activity (s) t, df p-value 
Prefrontal Cortex, medial 
Cg ant. 102.9 ± 0.94 n=13 103.9 ± 0.93 n=19 t=0.7353 df=30 0.47 
PrL 103.0 ± 0.93 n=13 104.2 ± 0.93 n=19 t=0.8824 df=30 0.38 
IL 103.2 ± 0.94 n=13 104.5 ± 0.95 n=19 t=0.9323 df=30 0.36 
Accumbens 
Acc core 105.4 ± 0.88 n=13 106.3 ± 0.84 n=19 t=0.6973 df=30 0.49 
Acc shell 106.6 ± 0.96 n=13 107.8 ± 0.92 n=19 t=0.8908 df=30 0.38 
Amygdala 
LA 101.2 ± 0.77 n=14 102.5 ± 0.65 n=19 t=1.278 df=31 0.21 
BLA 104.2 ± 0.79 n=14 105.5 ± 0.64 n=19 t=1.284 df=31 0.21 
CeA 104.4 ± 0.73 n=14 105.5 ± 0.55 n=19 t=1.219 df=31 0.23 
Hippocampus, dorsal 
CA1 102.0 ± 0.89 n=14 103.3 ± 0.70 n=17 t=1.146 df=29 0.26 
CA3 101.4 ± 0.91 n=14 102.4 ± 0.71 n=19 t=0.8713 df=31 0.39 
DG 108.5 ± 0.87 n=14 109.8 ± 0.64 n=18 t=1.214 df=30 0.23 
Hippocampus, ventral 
CA1 104.3 ± 0.62 n=12 103.6 ± 0.46 n=17 t=0.9868 df=27 0.33 
CA3 103.3 ± 0.40 n=14 103.1 ± 0.38 n=18 t=0.4023 df=30 0.69 
Miscellaneous 
PAG 104.5 ± 0.95 n=12 106.0 ± 0.71 n=16 t=1.264 df=26 0.22 
PVA - - - - 
LH 101.9 ± 0.50 n=14 101.4 ± 0.39 n=19 t=0.7512 df=31 0.46 
CPu 104.2 ± 0.94 n=13 105.8 ± 0.80 n=19 t=1.291 df=30 0.21 
MHb 101.8 ± 1.01 n=14 103.4 ± 0.75 n=19 t=1.331 df=31 0.19 
LHb 106.9 ± 1.24 n=14 109.0 ± 0.78 n=19 t=1.454 df=31 0.16 
PF 103.7 ± 0.49 n=14 103.6 ± 0.46 n=19 t=0.1915 df=31 0.85 
SN 102.3 ± 0.45 n=14 102.1 ± 0.44 n=18 t=0.3290 df=30 0.75 
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Table 4: A single electric foot shock changed CO activity in most of the analyzed brain 
areas at d35 post shock (Exp.2). Mice were shocked or non-shocked at d0, remained in their 
home cages, tested for hyperarousal at d28, and remained in their home cages for an additional 
week. Brains have been collected at d35 and CO staining was performed. ns non-shocked, s 
shocked mice; CO activity in mol/min/g (absolute values) 
 CO activity (ns) CO activity (s) t, df p-value 
Prefrontal Cortex, medial 
Cg ant. 103.1 ± 0.81 n=16 101.8 ± 0.79 n=19 t=1.147 df=33 0.26 
PrL 101.2 ± 0.80 n=16 103.6 ± 0.69 n=19 t=2.328 df=33 <0.05 
IL 102.1 ± 0.81 n=16 102.3 ± 0.69 n=19 t=0.1599 df=33 0.87 
Accumbens 
Acc core 103.5 ± 0.62 n=16 105.7 ± 0.62 n=19 t=2.530 df=33 <0.05 
Acc shell 105.1 ± 0.72 n=16 107.3 ± 0.73 n=19 t=2.148 df=33 <0.05 
Amygdala 
LA 100.7 ± 0.64 n=16 100.2 ± 0.67 n=19 t=0.5985 df=33 0.55 
BLA 102.7 ± 0.59 n=16 104.5 ± 0.56 n=19 t=2.092 df=33 <0.05 
CeA 104.8 ± 0.67 n=16 104.5 ± 0.64 n=19 t=0.3914 df=33 0.70 
Hippocampus, dorsal 
CA1 100.6 ± 0.79 n=16 102.7 ± 0.71 n=19 t=1.986 df=33 0.05 
CA3 99.36 ± 0.78 n=16 101.9 ± 0.78 n=19 t=2.258 df=33 <0.05 
DG 107.5 ± 0.73 n=16 109.6 ± 0.69 n=19 t=2.044 df=33 <0.05 
Hippocampus, ventral 
CA1 104.2 ± 0.82 n=15 106.8 ± 0.76 n=19 t=2.343 df=32 <0.05 
CA3 103.1 ± 0.85 n=15 105.8 ± 0.72 n=19 t=2.414 df=32 <0.05 
Miscellaneous 
PAG 103.3 ± 0.86 n=14 105.5 ± 0.67 n=19 t=2.058 df=31 <0.05 
PVA - - - - 
LH 100.7 ± 0.73 n=16 103.1 ± 0.84 n=19 t=2.061 df=33 <0.05 
CPu 103.0 ± 0.82 n=16 105.2 ± 0.62 n=19 t=2.102 df=33 <0.05 
MHb 100.1 ± 0.77 n=16 102.3 ± 0.68 n=19 t=2.143 df=33 <0.05 
LHb 107.7 ± 0.85 n=16 108.8 ± 0.93 n=19 t=0.8167 df=33 0.42 
PF 102.9 ± 0.82 n=16 105.5 ± 0.85 n=19 t=2.173 df=33 <0.05 
SN 102.7 ± 0.71 n=16 103.4 ± 0.77 n=19 t=0.6443 df=33 0.52 
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1.16 AMPAR-mEPSCs and GABAAR-mIPSCs (Exp. 3) 
In vitro patch-clamp recordings revealed no differences in amplitudes and 
frequencies of GABAAR-mIPSCs, measured 28 days after foot shock, in CA1 
and DG neurons of shocked compared to non-shocked mice (Figure 12). 
However, amplitudes but not frequencies of AMPAR-mEPSCs were significantly 
increased in DG but not in CA1 neurons of shocked mice 28 days after shock 
compared to non-shocked mice (Figure 13 and Figure 12). 
Note: AMPAR-mEPSC recordings were performed by CK Thoeringer. 
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Figure 12: Amplitudes of AMPAR-mEPSCs were significantly increased in DG neurons of 
shocked mice 28 days after foot shock compared to non-shocked (right bottom), whereas 
amplitudes and frequencies of GABAAR-mIPSCs in CA1 and DG neurons as well as 
AMPAR-mEPSCs in CA1 neurons and frequencies in DG neurons were similar (Exp. 3). 
Mice were shocked or non-shocked at d0, remained in their home cages until d28, acute brain 
slices were prepared and spontaneous activity were measured. Neurons were voltage-clamped 
at -60 mV for AMPAR-mEPSCs and at -40 mV for GABAAR-mIPSCs. GABAAR-mIPSCs: CA1: 
Nmice (non-shock/shocked) = 6/6; nslices (non-shocked/shocked) = 14/17; DG: Nmice (non-
shock/shocked) = 6/6; nslices (non-shocked/shocked) = 18/17;   AMPAR-mEPSCs: CA1: Nmice 
(non-shocked/shocked) = 6/7; nslices (non-shocked/shocked) = 19/35; DG: Nmice (non-
shocked/shocked) = 6/7; nslices (non-shocked/shocked) = 21/30. Statistical analysis were 
performed by unpaired t-test (AMPAR-mEPSCs (DG): p=0.03, t=2.212, df=49). *p<0.05 vs. non-
shocked  
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AMPAR-mEPSCs (DG)
 
Figure 13: Amplitudes of AMPAR-mEPSC were significantly increased in DG neurons of 
shocked mice 28 days after foot shock compared to non-shocked (Exp. 3). Representative 
traces of in vitro patch-clamp AMPAR-mEPSCs. 
 
1.17 Influence of PhTX on PTSD-like symptoms at d3 vs. d29 (Exp. 4)  
The increase in AMPAR-mEPSCs amplitudes may result from an increased 
surface expression of AMPARs, especially GluR1-containing AMPARs (O’Brien 
et al., 1998). Therefore, the physiological relevance of hippocampal GluR1 
receptors for remote contextual fear memories by intrahippocampal 
administration of philanthotoxin 433 (PhTX) was confirmed. Intrahippocampal 
application of PhTX reduced contextual fear at day 29 (remote fear memories), 
but not at day 3 (recent fear memories) after foot shock compared to vehicle 
application (Figure 14). 
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Figure 14: Philanthotoxin (intrahippocampal, 30 min before testing) decreased contextual 
fear at d29, but not at d3 post shock (Exp. 4). Mice were shocked (1.5 mA/ 2 s) in the 
chamber at d0 and remained in their home cages until testing. Mice were assigned to two 
groups with identical levels of sensitization on basis of their freezing responses to a 1’ tone at 
d1 or d27 (left; prospective PhTX classification). At day 3 or d29, PhTX was injected and mice 
were tested for contextual fear 30 min later. The percentage of time mice spent in freezing 
behavior was analyzed. Statistical analysis were performed by unpaired t-test (d29: p<0.001, 
t=4.70, df=23). n = 12-13 mice; *p<0.001 vs. non-shocked mice  
 
 
Changes in the glutamatergic system as a result of the traumatic event. 
Both, electrophysiological and behavioral studies, showed a long-term influence 
of the shock on the glutamatergic system (increased amplitudes in AMPAR-
mEPSC in the DG and reduced freezing responses at d29 after 
intrahippocampal injection of philanthotoxin 433). 
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1.18 Influence of preventive vs. therapeutic treatment with fluoxetine 
on PTSD-like symptoms and CO activity (Exp. 5) 
Non-shocked and shocked mice were assigned to two groups with identical 
freezing levels at sensitization on basis to their freezing responses (Figure 15).  
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Figure 15: For stratification, mice were exposed to a 1’ tone protocol at d28 (Exp. 5). Mice 
were shocked (1.5 mA/ 2 s) or non-shocked in the chamber at d0 and remained in their home 
cages for 28 days. At d28, mice were exposed to a neutral context (cylinder/ 1’ tone) to control 
for PTSD-like symptoms (left) and group the mice in a pseudo-randomized order for fluoxetine 
treatment (right, prospective fluoxetine classification). Percentage of time mice spent in freezing 
behavior was analyzed and data are represented as mean ± s.e.m. Statistical analysis were 
performed by unpaired t-test (p<0.001, t=10.54, df=60). n = 32 (non-shocked) or 39 (shocked) 
mice; *p<0.001 vs. non-shocked mice  
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Preventive (d1-28) or therapeutic (d28-56) treatment with fluoxetine 
(20 mg/kg/d) inhibited the increase of hyperarousal (Figure 16) and generalized 
and contextual fear responses (Figure 17). For statistical analysis see Table 5. 
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Figure 16: Four weeks of chronic fluoxetine treatment (preventive or therapeutic) 
reduced hyperarousal in shocked mice down to the level of non-shocked mice (Exp. 5). 
Mice were shocked (1.5 mA/ 2 s) or non-shocked in the chamber at d0 and remained in their 
home cages where they received fluoxetine (20 mg/kg/day) or vehicle via drinking water starting 
at d1 (preventive, left) or d28 (therapeutic, right). Statistical analysis were performed by 2-way 
repeated measures ANOVA (preventive: F4, 240, shock*INT=3.27, p<0.01; F4, 240, treat*INT=6.34, 
p<0.001; F4, 240, shock*treat*INT=2.86, p<0.05; therapeutic: F4, 236, shock*INT=3.85, p<0.01; 
F4, 236, treat*INT=10.77, p<0.001; F4, 236, shock*treat*INT=0.8748, p=0.48), followed by Newman-Keuls 
post-hoc test (preventive). npreventive = 16 per group, ntherapeutic = 11-12 (non-shocked) or 19 
(shocked) mice; *p<0.05 vs. non-shocked/ non-treated mice (ns-v); 
#
p<0.05 vs. shocked/ non-
treated mice (s-v); ns-v non-shocked, vehicle treated mice; ns-f non-shocked, fluoxetine treated 
mice; s-v socked, vehicle treated mice; s-f shocked fluoxetine treated mice 
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Figure 17:  Four weeks of 
chronic fluoxetine treatment 
(preventive or therapeutic) 
reduced generalized and 
contextual fear in shocked 
mice down to the level of non-
shocked mice (Exp. 5). Mice 
were shocked (1.5 mA/ 2 s) or 
non-shocked in the chamber at 
d0 and remained in their home 
cages where they received 
fluoxetine (20 mg/kg/day) or 
vehicle via drinking water 
starting at d1 (preventive, left) 
or d28 (therapeutic, right). After 
4 weeks of treatment, mice 
were tested (under fluoxetine) 
for hyperarousal (Figure 16) 
and afterwards for their freezing 
responses to a neutral context 
(cylinder/ 3’ tone), the hexagon, 
and the chamber. Statistical 
analysis were performed by 2-
way ANOVA (Table 5), followed 
by Newman-Keuls post-hoc 
test. npre. = 16 mice per group; 
nther. = 11-12 (non-shocked) or 
18-19 (shocked) mice; *p<0.05 
vs. non-shocked/ non-treated 
mice; 
#
p<0.05 vs. shocked/ non-
treated mice 
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Table 5: Statistical analysis of generalized and contextual fear responses under 
preventive or therapeutic treatment (Figure 9, Exp. 5). Statistical analyses were performed 
by 2-way ANOVA. 
 shock treatment shock*treatment 
 F p-level F p-level F p-level 
preventive 
Cylinder 36.28 (1,60) <0.001 39.03 (1,60) <0.001 38.50 (1,60) <0.001 
Tone 9.64 (1,60) <0.01 4.76 (1,60) <0.05 9.91 (1,60) <0.01 
Hexagon 122.67(1,60) <0.001 113.02 (1,60) <0.001 108.19 (1,60) <0.001 
Chamber 74.73 (1,60) <0.001 59.12 (1,60) <0.001 50.61 (1,60) <0.001 
therapeutic 
Cylinder 33.11 (1,57) <0.001 27.34 (1,57) <0.001 22.31 (1,57) <0.001 
Tone 18.14 (1,56) <0.001 11.65 (1,56) <0.001 9.85 (1,56) <0.01 
Hexagon 14.88 (1,58) <0.001 16.62 (1,58) <0.001 6.92 (1,58) <0.01 
Chamber 19.62 (1,58) <0.001 26.76 (1,58) <0.001 12.45 (1,58) <0.001 
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After 1 month, shocked mice showed increased CO activity in several brain 
regions including the prelimbic cortex (PrL), the accumbens (AccC, AccSh), the 
basolateral amygdaloid nucleus (BLA), the dorsal (CA1, CA3, DG) and ventral 
(CA1v, CA3v) hippocampus, the periaqueductal gray (PAG), the lateral 
hypothalamic area (LH), the striatum (CPu), and the parafascicular thalamic 
nucleus (PF) (Exp. 1 and 2). Interestingly, in preventive treated, shocked mice, 
these CO activity increases could not be detected in all structures. The following 
brain regions, which showed an increase in CO activity without treatment, were 
affected by preventive treatment with fluoxetine, i.e. the CO activity was 
significantly lower as in shocked, vehicle treated mice: the prelimbic cortex 
(PrL), the accumbens nucleus shell (AccSh), the basolateral amygdaloid 
nucleus (BLA), the CA1 and the DG in the dorsal hippocampus, the 
periaqueductal gray (PAG), the lateral hypothalamic area (LH), and the 
parafascicular thalamic nucleus (PF). However, there were still regions which 
were not affected by preventive treatment with fluoxetine, including the Acc c, 
the CA3 (dorsal), the ventral hippocampus (CA1, CA3), and the CPu (Figure 18 
and Table 6). In contrast, therapeutic treatment with fluoxetine had no influence 
on the CO activity and the brain regions, which showed increased levels in CO 
activity due to the shock, showed no differences between fluoxetine treated and 
vehicle treated mice (Figure 19 and Table 7).  
 
 
Influence of preventive or therapeutic treatment with fluoxetine on PTSD-
like symptoms and CO activity 
Preventive and therapeutic treatment with fluoxetine in shocked mice abolished 
PTSD-like symptoms. Under preventive treatment, shocked, fluoxetine treated 
mice showed increased CO activity only in a few regions (Acc core, CA3 dorsal, 
CA1+3 ventral), whereas under therapeutic treatment the CO activity in the 
analyzed brain regions of shocked, fluoxetine treated mice was significantly 
increased in comparison to non-shocked, vehicle treated mice and similarly to 
shocked, vehicle treated mice. Consequently preventive, but not therapeutic 
treatment prevented the development of chronic changes in CO activity. 
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Figure 18: Preventive treatment with fluoxetine prevented the increase in CO activity in 
response to the shock (Exp. 5). Mice were shocked or non-shocked at d0, remained in their 
home cages where they were treated with fluoxetine (20 mg/kg/d) from d1 until d35. Mice were 
tested for hyperarousal and generalized and contextual fear responses (d28-30; Figure 16 and 
18), and remained in their home cages for an additional week. Brains have been collected and 
CO staining was performed. Statistical analysis were performed by 2-way ANOVA (Table 6), 
followed by Newman-Keuls post-hoc test. ns non-shocked mice; s shocked mice; *p<0.05 vs. 
non-shocked/ vehicle-treated mice; 
#
p<0.05 vs. shocked/ vehicle-treated mice; CO activity in 
mol/min/g (absolute values) 
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Table 6: Preventive treatment with fluoxetine prevented the increase in CO activity in 
response to the shock (Exp. 5). Mice were shocked or non-shocked at d0, remained in their 
home cages where they were treated with fluoxetine (20 mg/kg/d) from d1 until d35. Mice were 
tested for hyperarousal and generalized and contextual fear responses (d28-30; Figure 16 and 
18), and remained in their home cages for an additional week. Brains have been collected and 
CO staining was performed. ns non-shocked mice; s shocked mice; S p-value of factor shock; T 
p-value of factor treatment; S*T p-value of the interaction; *p<0.05 vs. non-shocked/ vehicle-
treated mice; 
#
p<0.05 vs. shocked/ vehicle-treated mice; CO activity in mol/min/g (absolute 
values); (to be continued on the next page) 
Note: Data are graphically depicted in Figure 18. 
 CO activity 
ns/vehicle 
CO activity 
ns/fluoxetine 
CO activity 
s/vehicle 
Co activity 
s/fluoxetine 
 
S 
 
T 
 
S*T 
Prefrontal Cortex, medial 
Cg ant. 151.0 ± 1.01 
n=15 
151.3 ± 1.53 
n=15 
152.7 ± 1.84 
n=14 
149.7 ± 1.80 
n=15 
0.99 
 
0.68 
 
0.40 
 
PrL 153.0 ± 0.67 
n=15 
153.7 ± 1.20 
n=15 
162.5 ± 1.88 
n=14   * 
153.3 ± 1.41 
n=15  
#
 
<0.001 
 
<0.001 
 
<0.001 
 
IL 154.3 ± 1.30 
n=15 
155.3 ± 1.69 
n=15 
154.2 ± 1.80 
n=14 
154.8 ± 1.80 
n=15 
0.76 
 
0.37 
 
0.92 
 
Accumbens 
Acc core 155.7 ± 1.44 
n=15 
158.6 ± 1.97 
n=15 
167.5 ± 2.44 
n=14   * 
164.3 ± 1.17 
n=15    
<0.001 
 
0.94 
 
<0.05 
 
Acc shell 157.6 ± 1.54 
n=15 
159.1 ± 1.74 
n=15 
168.8 ± 2.04 
n=14   * 
165.1 ± 1.64 
n=15   
#
 
<0.001 
 
0.35 
 
<0.05 
 
Amygdala 
LA 156.5 ± 1.334 
n=15 
157.8 ± 1.631 
n=15 
156.0 ± 2.02 
n=14 
158.5 ± 2.21 
n=15 
0.75 
 
0.33 
 
0.94 
 
BLA 162.6 ± 1.41 
n=15 
162.5 ± 1.96 
n=15 
172.0 ± 2.60 
n=14   * 
163.4 ± 2.43 
n=15   
#
 
<0.01 
 
<0.01 
 
<0.01 
 
CeA 158.5 ± 1.51 
n=15 
159.1 ± 2.46 
n=15 
157.7 ± 2.24 
n=14 
159.4 ± 2.35 
n=15 
0.98 
 
0.61 
 
0.92 
 
Hippocampus, dorsal 
CA1 144.3 ± 1.33 
n=15 
145.1 ± 1.84 
n=15 
150.3 ± 1.98 
n=14   * 
146.2 ± 2.11 
n=15   
#
 
<0.05 
 
0.07 
 
0.08 
 
CA3 144.3 ± 1.38 
n=15 
146.3 ± 2.03 
n=15 
153.3 ± 2.27 
n=14   * 
151.3 ± 1.98 
n=15  
<0.001 
 
0.48 
 
0.15 
 
DG 162.7 ± 1.35 
n=15 
161.9 ± 2.04 
n=15 
171.0 ± 2.10 
n=14   * 
162.2 ± 1.68 
n=15   
#
 
<0.01 
 
<0.001 
 
<0.01 
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Table 6: Preventive treatment with fluoxetine prevented the increase in CO activity in 
response to the shock (Exp. 5) (in continuation). 
Hippocampus, ventral 
CA1 163.3 ± 1.45 
n=15 
164.7 ± 2.23 
n=15 
170.7 ± 2.48 
n=14   * 
171.4 ± 2.20 
n=15 
<0.001 
 
0.96 
 
0.60 
 
CA3 155.6 ± 1.51 
n=15 
156.7 ± 2.12 
n=15 
165.1 ± 2.35 
n=14   * 
168.7 ± 2.22 
n=15 
<0.001 
 
0.61 
 
0.80 
 
Miscellaneous 
PAG 159.1 ± 1.59 
n=15 
160.1 ± 1.81 
n=15 
165.5 ± 2.65 
n=14   * 
155.5 ± 2.61 
n=15   
#
 
0.39 
 
<0.01 
 
<0.01 
 
PVA 159.1 ± 1.92 
n=15 
161.1 ± 1.86 
n=15 
159.8 ± 2.13 
n=14 
162.0 ± 1.84 
n=15 
0.50 
 
0.38 
 
0.82 
 
LH 150.2 ± 1.83 
n=15 
150.0 ± 2.22 
n=15 
160.7 ± 2.42 
n=14   * 
153.0 ± 2.36 
n=15   
#
 
<0.001 
 
<0.05 
 
<0.05 
 
CPu 157.8 ± 1.39 
n=15 
158.8 ± 1.97 
n=15 
164.0 ± 2.24 
n=14   * 
164.1 ± 2.07 
n=15 
<0.01 
 
0.91 
 
0.71 
 
MHb 151.4 ± 1.62 
n=15 
151.4 ± 2.12 
n=15 
155.9 ± 2.22 
n=14 
152.4 ± 2.22 
n=15 
0.16 
 
0.32 
 
0.27 
 
LHb 165.6 ± 1.83 
n=15 
164.7 ± 2.21 
n=15 
170.6 ± 1.83 
n=14 
164.6 ± 1.99 
n=15   
#
 
0.19 
 
<0.05 
 
0.14 
 
PF 159.2 ± 1.71 
n=15 
160.9 ± 1.83 
n=15 
166.9 ± 2.45 
n=14   * 
162.4 ± 2.16 
n=15   
#
 
<0.01 
 
0.17 
 
<0.05 
 
SN 153.3 ± 1.46 
n=15 
151.8 ± 1.99 
n=15 
151.7 ± 2.55 
n=14 
159.7 ± 1.92 
n=15   
#
 
0.06 
 
0.18 
 
<0.05 
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Figure 19: Therapeutic treatment with fluoxetine did not abolish the increased CO activity 
in response to the shock (Exp. 5) Mice were shocked or non-shocked at d0 and remained in 
their home cages where they were treated with fluoxetine (20 mg/kg/d) or vehicle from d28 until 
d72. Mice were tested for hyperarousal and generalized and contextual fear responses, and 
remained in their home cages for an additional week. Brains have been collected at d72 and 
CO staining was performed. ns non-shocked mice; s shocked mice; *p<0.05 vs. non-shocked/ 
vehicle treated mice (same data as Table 7); CO activity in mol/min/g (absolute values) 
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Table 7: Therapeutic treatment with fluoxetine did not change the increased CO activity 
in response to the shock (Exp. 5). Mice were shocked or non-shocked at d0 and remained in 
their home cages where they were treated with fluoxetine (20 mg/kg/d) or vehicle from d28 until 
d72. Mice were tested for hyperarousal and generalized and contextual fear responses, and 
remained in their home cages for an additional week. Brains have been collected at d72 and 
CO staining was performed. ns non-shocked mice; s shocked mice; S p-value of factor shock; T 
p-value of factor treatment; S*T p-value of the interaction; *p<0.05 vs. non-shocked/ vehicle 
treated mice; CO activity in mol/min/g (absolute values); (to be continued on the next page)  
Note: Data are graphically depicted in Figure 19. 
 CO activity  
ns/vehicle 
CO activity 
ns/fluoxetine 
CO activity  
s/vehicle 
CO activity 
s/fluoxetine 
 
S 
 
T 
 
S*T 
Prefrontal Cortex, medial 
Cg ant. 124.3 ± 4.64 
n=13 
122.9 ± 4.48 
n=11 
124.3 ± 3.40 
n=20 
121.5 ± 5.12 
n=18 
0.87 
 
0.64 
 
0.88 
 
PrL 127.8 ± 3.28 
n=13 
125.5 ± 3.59 
n=11 
141.6 ± 2.73 
n=20   * 
137.7 ± 4.99 
n=18   * 
<0.01 
 
0.44 
 
0.83 
 
IL 139.8 ± 5.23 
n=13 
139.2 ± 4.90 
n=11 
139.7 ± 3.47 
n=20 
137.6 ± 5.23 
n=18 
0.87 
 
0.78 
 
0.88 
 
Accumbens 
Acc core 112.6 ± 4.67 
n=13 
117.8 ± 3.91 
n=11 
125.3 ± 3.39 
n=20   * 
132.0 ± 4.37 
n=18   * 
<0.01 
 
0.16 
 
0.86 
 
Acc shell 152.8 ± 5.91 
n=13 
154.5 ± 4.88 
n=11 
163.2 ± 4.38 
n=20 
170.4 ± 5.81 
n=18 
 
<0.05 
 
0.42 
 
0.63 
 
Amygdala 
LA 162.6 ± 4.69 
n=13 
160.0 ± 6.23 
n=11 
160.9 ± 4.16 
n=20 
163.6 ± 4.38 
n=18 
0.84 
 
0.99 
 
0.59 
 
BLA 166.7 ± 4.73 
n=13 
166.0 ± 5.95 
n=11 
178.5 ± 2.71 
n=20   * 
179.4 ± 3.96 
n=18    * 
<0.01 
 
0.98 
 
0.85 
 
CeA 165.9 ± 4.92 
n=13 
161.9 ± 6.55 
n=11 
165.7 ± 4.16 
n=20 
166.2 ± 4.25 
n=18 
0.68 
 
0.71 
 
0.65 
 
Hippocampus, dorsal 
CA1 116.0 ± 3.23 
n=13 
115.0 ± 5.07 
n=11 
128.2 ± 2.97 
n=20   * 
132.6 ± 4.05 
n=18   * 
<0.001 
 
0.66 
 
0.49 
 
CA3 108.4 ± 3.80 
n=13 
109.1 ± 5.63 
n=11 
138.1 ± 3.83 
n=20   * 
152.1 ± 3.99 
n=17   * 
<0.001 
 
0.15 
 
0.20 
 
DG 137.1 ± 4.85 
n=13 
134.5 ± 7.11 
n=11 
152.3 ± 4.16 
n=20   * 
158.5 ± 5.33 
n=18   * 
<0.001 
 
0.75 
 
0.41 
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Table 7: Therapeutic treatment with fluoxetine did not change the increased CO activity 
in response to the shock (Exp. 5, in continuation). 
Hippocampus, ventral 
CA1 178.0 ± 5.47 
n=13 
177.6 ± 7.06 
n=11 
179.6 ± 4.29 
n=20 
184.5 ± 5.07 
n=17 
<0.01 
 
0.89 
 
0.83 
 
CA3 163.8 ± 4.71 
n=13 
164.4 ± 6.55 
n=11 
164.0 ± 4.46 
n=20 
169.8 ± 5.14 
n=17 
<0.05 
 
0.74 
 
0.83 
 
Miscellaneous 
PAG 139.2 ± 4.77 
n=13 
135.1 ± 5.57 
n=11 
154.4 ± 3.81 
n=20   * 
155.8 ± 4.14 
n=18   * 
<0.001 
 
0.76 
 
0.54 
 
PVA 107.9 ± 3.25 
n=13 
109.9 ± 4.62 
n=11 
109.4 ± 2.56 
n=20 
108.9 ± 3.46 
n=18 
0.93 
 
0.84 
 
0.72 
 
LH 155.3 ± 5.05 
n=13 
152.9 ± 5.91 
n=11 
151.3 ± 4.70 
n=20 
158.4 ± 5.54 
n=17 
0.07 
 
0.87 
 
0.55 
 
CPu 140.7 ± 5.21 
n=13 
137.6 ± 7.00 
n=11 
136.8 ± 3.65 
n=20 
141.2 ± 5.65 
n=17 
0.97 
 
0.90 
 
0.48 
 
MHb 133.4 ± 4.52 
n=13 
130.5 ± 6.10 
n=11 
133.0 ± 4.02 
n=20   * 
139.3 ± 4.60 
n=17   * 
<0.01 
 
0.45 
 
0.59 
 
LHb 119.5 ± 6.64 
n=13 
123.8 ± 8.98 
n=11 
124.4 ± 5.92 
n=20 
115.2 ± 6.77 
n=17 
0.80 
 
0.73 
 
0.35 
 
PF 147.3 ± 3.97 
n=13 
143.1 ± 7.06 
n=11 
149.8 ± 4.68 
n=20 
153.4 ± 5.70 
n=17 
<0.05 
 
0.75 
 
0.73 
 
SN 158.4 ± 4.28 
n=14 
155.9 ± 7.61 
n=10 
155.3 ± 4.28 
n=20 
161.5 ± 5.05 
n=17 
0.84 
 
0.54 
 
0.57 
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1.19 Relapse of PTSD-like symptoms after 4 weeks of wash-out 
subsequent to therapeutic, but not preventive treatment (Exp. 6) 
At the end of the preventive treatment, mice were tested for freezing behavior in 
the cylinder (1’ tone) to look for the PTSD-like symptoms and the efficiency of 
fluoxetine treatment (Figure 20, top). The therapeutically treated mice were 
tested at d28, to look for the PTSD-like symptoms and assigned them into 2 
groups with identical freezing levels, and at d56 to scrutinize for the efficiency of 
fluoxetine treatment (Figure 20, bottom).  
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Figure 20: To look for the presence of PTSD-like symptoms and the efficiency of 
fluoxetine treatment, mice were exposed to a 1’ tone protocol (Exp. 6). Mice were shocked 
(1.5 mA/ 2 s) or non-shocked in the chamber at d0 and remained in their home cages where 
they received fluoxetine (20 mg/kg/day) or vehicle via drinking water starting at d1 (preventive, 
above) or d28 (therapeutic, bottom) for 28 days. At d28 mice were exposed to a neutral context 
(cylinder/ 1’ tone) to look for PTSD-like symptoms and the efficiency of fluoxetine treatment 
(preventive treatment) or the existing of PTSD-like symptoms (therapeutic treatment) and 
stratification for the prospective fluoxetine treatment. At d56 therapeutically treated mice were 
exposed to the cylinder again to measure the efficiency of fluoxetine treatment. Statistical 
analysis were performed with 2-way ANOVA (preventive: F1, 58, shock=98.48, p<0.001; F1, 58, treat. 
=62.06, p<0.001; F1, 58, shock*treat.=54.04, p<0.001; therapeutic: F1, 59, shock=26.67, p<0.001; 
F1, 59, treat.=5.58, p<0.001; F1, 59, shock*treat.=19.03, p<0.001), followed by Newman-Keuls post-hoc 
test or unpaired t-test (therapeutic: p<0.001, t=12.52, df=60). npreventive = 15-16 mice per group, 
ntherapeutic = 32 mice per group (2 groups) or ntherapeutic = 15-16 mice per group (4 groups); 
*p<0.05 vs. non-shocked/ vehicle-treated mice; 
#
p<0.05 vs. shocked/ vehicle-treated mice 
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Four weeks after the end of fluoxetine treatment, the PTSD-like symptoms in 
preventively treated mice stayed on baseline level (level of non-shocked/ 
vehicle treated mice) both in hyperarousal (Figure 21) and in the generalized 
and contextual fear (Figure 22), whereas in therapeutically treated mice 
symptoms relapsed to the level of shocked vehicle treated mice. 
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Figure 21: Four weeks after the end of the preventive or therapeutic treatment with 
fluoxetine, mice were tested for hyperarousal (Exp. 6). Mice were shocked (1.5 mA/ 2 s) or 
non-shocked in the chamber at d0 and remained in their home cages, where they received 
fluoxetine (20 mg/kg/day) or vehicle via drinking water, starting at d1 until d28 (preventive, left) 
or at d28 until d56 (therapeutic, right). After additional 4 weeks (drug-free), mice were tested for 
hyperarousal symptomatology (ASR). Statistical analysis were performed by 2-way repeated 
measures ANOVA (preventive: F4, 236, shock*INT=0.46, p=0.76; F4, 236, treat*INT.=3.33, p<0.01; 
F4, 236, shock*treat*INT=0.19, p=0.94; therapeutic: F4, 232, shock*INT= 3.28, p<0.01; F4, 232, treat*INT=0.33, 
p=0.85; F4, 232, shock*treat*INT.=1.45, p=0.22), followed by Newman-Keuls post-hoc test. 
npre. + wash-out = 15-16, nther. + wash-out = 14-15; ns-v non-shocked, vehicle treated mice; ns-f non-
shocked, fluoxetine treated mice; s-v socked, vehicle treated mice; s-f shocked fluoxetine 
treated mice; *p<0.05 s-v vs. ns-v mice; 
#
p<0.05 s-f vs. s-v mice 
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Figure 22: Four weeks after 
the end of preventive or 
therapeutic treatment with 
fluoxetine, mice were tested 
for generalized and 
contextual fear (Exp. 6).  
Mice were shocked (1.5 mA/ 
2 s) or non-shocked in the 
chamber at d0 and remained 
in their home cages, where 
they received fluoxetine 
(20 mg/kg/day) or vehicle via 
drinking water, starting at d1 
until d28 (preventive, left) or 
starting at d28 until d56 
(therapeutic, right). After 
additional 4 weeks (drug-free) 
mice were tested for 
hyperarousal (Figure 22) and 
afterwards to a neutral context 
(cylinder/ 3’ tone), the 
hexagon, and the sensitized 
chamber. The percentage of 
time mice spent in freezing 
behavior were analyzed. 
Statistical analysis were 
performed with 2-way ANOVA 
(Table 8), followed by 
Newman-Keuls post-hoc test. 
nprev. + wash. = 15-16, nther. + wash. 
= 16; *p<0.05 vs. non-
shocked/ vehicle treated mice. 
#
p<0.05 vs. shocked/ vehicle 
treated mice.  
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Table 8: Statistical analysis of generalized and contextual fear responses 4 weeks after 
the end of preventive or therapeutic treatment (Figure 22, Exp. 6). Statistical analysis was 
performed with 2-way ANOVA. 
 shock treatment shock*treatment 
 F p-level F p-level F p-level 
preventive 
Cylinder 38.03 (1,59) <0.001 28.46 (1,59) <0.001 23.81 (1,59) <0.001 
Tone 29.01 (1,59) <0.01 24.76 (1,59) <0.001 20.22 (1,59) <0.001 
Hexagon 23.75 (1,59) <0.001 23.64 (1,59) <0.001 24.03 (1,59) <0.001 
Chamber 55.56 (1,59) <0.001 53.09 (1,59) <0.001 53.26 (1,59) <0.001 
therapeutic 
Cylinder 51.28 (1,60) <0.001 2.12 (1,60) 0.15 2.62 (1,60) 0.11 
Tone 79.79 (1,60)  <0.001 0.01 (1,60) 0.92 0.40 (1,60) 0.53 
Hexagon 21.04 (1,60) <0.001 0.48 (1,60) 0.49 0.50(1,60) 0.48 
Chamber 21.97 (1,60) <0.001 0.00 (1,60) 1.00 0.87(1,60) 0.35 
 
 
Changes of PTSD-like symptoms and CO activity four weeks after the end 
of preventive or therapeutic treatment with fluoxetine 
Four weeks after the end of fluoxetine treatment, the PTSD-like symptoms in 
the preventively treated group were still at baseline level (i.e. were prevented), 
whereas there was evidence of a relapse in hyperarousal symptomatology and 
generalized and contextual fear responses in the therapeutically treated group. 
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Discussion 
The motivation behind this study was to advance the development of novel 
PTSD therapy strategies by providing a better understanding of the 
neurobiological mechanisms in an animal model of the disease with high face, 
construct, and predictive validity. 
In our mouse model of PTSD, a brief, inescapable electric foot shock, after an 
incubation time of 1 month, led to PTSD-like symptoms including hyperarousal 
symptomatology (Figure 8), generalized and contextual fear (Figure 9), and 
avoidance behavior (Figure 10) as well as increased CO activity in the prelimbic 
cortex, the hippocampus, the basolateral amygdaloid nucleus, and the 
periaqueductal gray, among others (Table 2 and 4). However, in the early 
aftermath of a trauma, neither the PTSD-like symptoms (Figure 11; Siegmund 
and Wotjak, 2007) nor changes in the CO activity were observed (Table 3). 
Furthermore, the preventive as well as the therapeutic treatment with fluoxetine 
(an SSRI belonging to the first-line treatment of PTSD) inhibited the PTSD-like 
symptoms, hyperarousal symptomatology (Figure 16) and generalized and 
contextual fear (Figure 17), after 4 weeks of treatment, whereas changes in the 
CO activity were affected only after the preventive (Figure 18), but not after the 
therapeutic treatment (Figure 19).  
In addition, discontinuation of treatment led to relapse of PTSD-like symptoms 
including hyperarousal symptomatology (Figure 21) as well as generalized and 
contextual fear (Figure 22) in the therapeutically, but not in the preventively 
treated group. 
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1.20 Traces of a trauma 
1.20.1 Face validity 
In humans, PTSD is defined by the presence of trauma related memories, 
hyperarousal, emotional numbing, and avoidance of trauma-related stimuli for at 
least 1 month (DSM IV). To mimic these obvious behavioral symptoms in our 
mouse model of PTSD, the present study used a brief, inescapable electric foot 
shock (the traumatic event for the mice) which had no influence on the 
hyperarousal symptomatology (Figure 11) nor the generalized and contextual 
fear (Siegmund and Wotjak, 2007) 2 days after the trauma. In contrast, after an 
incubation time of 4 weeks, the traumatic event led to PTSD-like symptoms as 
hyperarousal symptomatology (increased acoustic startle responses (ASR); 
Figure 8), generalized and contextual fear (increased freezing responses to the 
cylinder, the tone, the hexagon, and the chamber; Figure 9), and avoidance 
behavior (increased avoidance in the conditioned odor avoidance test (CODA); 
Figure 10) in shocked mice as compared to non-shocked. These behavioral 
data are in-line with previous studies in our mouse model (Golub et al., 2009; 
Pamplona et al., 2011) and other animal models of PTSD, for example Wang 
and colleagues using an underwater trauma (Wang et al. 2000), Adamec and 
colleagues using exposure to a predator as stressor (Adamec et al., 1998) or 
Cohen and colleagues using predator (scent) stress (Cohen et al., 2003, 2008). 
As mentioned above, in the early aftermath of a trauma, the PTSD-like 
symptoms could not be detected and developed over a time course of 4 weeks. 
Nevertheless, if the mice only remained in their home-cage after the traumatic 
event, the PTSD-like symptoms peak around day 28 and are diminished with 
time and were not detectable after 3 to 5 months. The reason for this 
phenomenon might be the brief, electric foot shock (1.5 mA/ 2 s) which is 
probably not effective enough to elicit PTSD-like symptoms in mice for a longer 
time period, but more aversive foot shock protocols are precluded by the local 
ethics rules and the animal protection law. It is unclear whether other animal 
models of PTSD show PTSD-like symptoms for a longer time period. In most 
studies, the animals were tested within days or weeks after the traumatic event 
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(Adamec and Shallow, 1993; Cohen et al., 2003; Belda et al., 2008) and not 
after months.  
This phenomenon limited the time interval after the traumatic event in which 
studies could be performed. Even so, the observation of significant effects 
between shocked vs. non-shocked and treated vs. non-treated mice almost 
3 months after the traumatic event was possible (ASR - Figure 21; generalized. 
and contextual fear - Figure 22; right side). 
Nevertheless, the decrease of PTSD symptoms might be the explanation for the 
marginal differences in the hyperarousal symptomatology 3 months after the 
traumatic event (Exp. 6: therapeutic treatment + wash-out; Figure 21). 
PTSD is a clinical symptomatological diagnosis and some cardinal symptoms 
are reflected in our animal model; however the neurobiological basis of the 
disorder is still not completely understood, thus preventing the development of 
specific therapeutic strategies. Therefore it is necessary to investigate the 
neurobiological mechanism. 
1.20.2 Construct validity 
Although there is a huge amount of literature concerning molecular changes in 
PTSD patients as well as in animal models of PTSD, little is known about the 
time-course of these molecular changes – e.g. which are principally involved in 
the initiation of the pathophysiology and which are merely consequences of 
others. Focusing on the tonic changes of neuronal activity which are considered 
surrogate markers of long-lasting disorders such PTSD, a lot of molecular und 
structural changes after a traumatic event, both in humans and animals, have 
been identified. For example, several studies showed the reduction of the 
hippocampal volume in PTSD patients (Stein et al., 1994; Bremner et al., 1995) 
which have also been observed in mice (Golub et al., 2011), the enhancement 
of AMPA receptor signaling (Thoeringer et al., submitted), and increased kinase 
(pAKT and GSK-3β) activity (Dahlhoff et al., 2010) have been described. The 
group of Gonzalez-Lima (Gonzalez-Lima and Garrosa, 1991; Gonzalez-Lima 
and Cada, 1994; Poremba and Jones, 1998) and others (Hevner and Wong-
Riley, 1989, 1990; Zhang et al., 2006) used CO as a neuronal activity marker 
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for example in the classical conditioning paradigms. Therefore CO activity has 
been identified as a valuable tool for detecting changes of neuronal activity. 
Alterations of CO activity as a consequence of the traumatic event 
For behavioral correlates to the expected CO activity changes between shocked 
and non-shocked mice, mice were tested for PTSD-like symptoms such as 
hyperarousal symptomatology, generalized and contextual fear, and avoidance 
behavior. To avoid acute influence of testing, CO staining was performed 
1 week after the last behavioral test. Brain regions linked to emotions in 
general, to fear, or learning were analyzed. The brain regions with their relevant 
function in detail:  
• The medial prefrontal cortex (mPFC) including the subregions Cg1, PrL, 
and IL because of its relevance for executive functions, including 
decision-making, attention control, working memory, stress response, 
behavioral inhibition, and moderating the correct social behavior 
(Yamasaki et al., 2002; Heidbreder and Groenewegen, 2003; Morgane et 
al., 2005; Rossetti and Carboni, 2005; Shad et al., 2011; Staiti et al., 
2011). 
• The nucleus accumbens (Acc) including both sub-nuclei (AccC and 
AccSh) because of its important role in fear and aggression. Additionally, 
this structure is critical for the acquisition and expression behavior; a 
number of reward related behaviors, and processes specific information 
about reward availability (Knutson and Cooper, 2005; Wise, 2006; Day 
and Carelli, 2007; Bradfield and McNally, 2010). 
• The amygdala (AMY) including the lateral (LA), basolateral (BLA), and 
central amygdaloid nuclei (CeA) as a major structure involved in 
emotional learning and attention (Adolphs et al., 1995; LeDoux, 2001). 
• The dorsal hippocampus including CA1, CA3, and the dentate gyrus and 
the ventral hippocampus (CA1, CA3) for their relevance in learning and 
memory consolidation  (McClelland et al., 1995; Norman and O’Reilly, 
2003; Yassa and Stark, 2011). 
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• The periaqueductal gray (PAG) which is involved in the regulation of 
defensive behavior (Carrive, 1993; Yamashita et al., 2011). 
• The paraventricular thalamic nucleus ant. (PVA) which is activated by 
stress and governs control over the HPA axis (Antoni, 1986; Whitnall, 
1993). 
• The lateral hypothalamic area (LH) involved in fear regulation; (Wise, 
1974; Elmquist et al., 1999; Swanson, 2000). 
• The dorsal striatum (CPu) activated by intense and aversive stimuli and 
involved in learning and memory (Packard and Knowlton, 2002). 
• The habenula including the medial (MHb) and lateral (LHb) part involved 
in pain processing, fear, learning, and stress (Sutherland and Nakajima, 
1981; Benabid and Jeaugey, 1989; Murphy et al., 1996; Hikosaka, 2010). 
• The parafascicular thalamic nucleus (PF) (Steriade and Deschenes, 
1984; Vogt et al., 2008). And: 
• the substantia nigra (SN) which is involved, among others, in learning 
(Da Cunha et al., 2009). 
Significant increase in the CO activity in shocked compared to non-shocked 
mice was found in the following brain regions: the prelimbic cortex (PrL), the 
accumbens (core and shell), the basolateral amygdaloid nucleus, the dorsal 
hippocampus (CA1, CA3 and DG), the ventral hippocampus (CA1 and CA3), 
the periaqueductal gray (PAG), the lateral hypothalamic area (LH), the striatum 
(CPu), the medial part of the habenula (MHb), and the parafascicular thalamic 
nucleus (PF). In contrast, in the cingulate (Cg ant.) and infralimbic cortex (IL), 
the lateral and central amygdaloid nucleus (LA and CeA), the paraventricular 
thalamic nucleus (PVN), the lateral part of the habenula (LHb), and the 
substancia nigra (SN) showed no differences in the CO activity (Table 2, Table 
3, Table 6, and Table 7). 
It is interesting that in all of the analyzed brain regions either increases or no 
changes in CO activity were observed; no structure displayed a decrease. This 
observation might indicate a limitation of the method. However, there are 
Discussion 
 
 
62
several points which underscore the quality of this method: First, the fact that 
the CO activity at day 9 after the foot shock, so in the early aftermath of the 
trauma, was not affected at all (Table 3). These findings give important insight 
into the neuronal network mechanism during the post-traumatic incubation 
period; further scrutiny of these mechanisms might unravel novel targets for 
preventive therapy. Second, the remarkable reproducibility of the CO staining 
(Table 9), which showed a high consistency between the measurements. Third, 
the fact that regions e.g. which are localized in the same slice and consequently 
on the same slide and in the same staining chamber, showed differences in 
activity changes. For example, the basolateral amygdaloid nucleus (BLA) 
always showed a significant increase in CO activity in shocked compared to 
non-shocked mice after fear incubation, whereas the lateral and central 
amygdaloid nuclei (LA and CeA) showed no changes in CO activity at any time. 
The same was observed in the medial prefrontal cortex, where the prelimbic 
cortex (PrL) showed a significant increase in shocked compared to non-
shocked mice, whereas the cingulate cortex (Cg ant.) and the infralimbic cortex 
(IL) did not. In summary, the CO staining proved for analyzing tonic changes in 
neuronal activity in the brain in our mouse model of PTSD. Furthermore, 
Shumake and colleagues found in congenitally helpless rats decreased levels of 
CO activity compared to non-helpless rats (Shumake et al., 2002). This 
increase was normalized after fluoxetine treatment. In conclusion, PTSD is 
equitable with an increase in the CO activity. 
To compare the activation patterns from this study with other studies, Lui and 
colleagues (2009) measured the resting state activities via functional MRI 
(fMRI) in (human) survivors within 25 days after the Wenchuan 8.0 earthquake 
in China (2008). They found increased resting state activity in the prefrontal 
cortex, the nucleus accumbens, the hippocampus, as well as the amygdala. 
(The authors did not further subdivide these brain regions.) These findings are 
in consent with the results from the present study, where the hippocampus, the 
basolateral amygdaloid nucleus (BLA), the periaqueductal gray (PAG), the 
prelimbic cortex (PrL), and the nucleus accumbens (AccC and AccSh) showed 
significantly increased CO activity. 
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Table 9: Overview of CO activity changes in the regions of interest (ROI) of all 
experiments. Left: Shocked (vehicle treated) mice were compared to non-shocked (vehicle 
treated) mice (control). Right: Shocked, fluoxetine treated mice were compared to non-shocked, 
fluoxetine treated mice (control). Red: significant increase in CO activity; green: no difference in 
CO activity if compared to non-shocked, vehicle treated mice and significant decrease if 
compared to shocked, vehicle treated mice; grey: no change in CO activity. 
 shocked / non-shocked fluox / veh 
Post shock d9 d35 d37 d42 d65  d37 d65 
Nr. of experiment 2 2 5 1 5 5 5 
Prefrontal Cortex, medial 
Cg ant.        
PrL        
IL        
Accumbens 
Acc core        
Acc shell        
Amygdala 
LA        
BLA        
CeA        
Hippocampus, dorsal 
CA1        
CA3        
DG        
Hippocampus, ventral 
CA1        
CA3        
Miscellaneous 
PAG        
PVN        
LH     p=0.07   
CPu        
MHb        
LHb        
PF        
SN        
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Considering these findings, the first working hypothesis “A traumatic event (a 
single electric foot shock) changes the tonic activity (cytochrome c oxidase) in 
the brain one month after the trauma.” can be accepted. 
However, CO activity is a marker for neuronal activity, but to this point the 
molecular events leading to it remain unclear. Therefore, the glutamatergic and 
gabaergic system in the dorsal hippocampus, CA1 region and dentate gyrus, 
were investigated. 
Recordings of GABAA-mIPSCs in the CA1 and the dentate gyrus in the dorsal 
hippocampus of shocked mice showed no changes in consequence of the 
traumatic event, neither in the amplitudes nor in frequencies, compared to non-
shocked animals at d28. However, both, the increased amplitudes in AMPAR-
mEPSCs in the dentate gyrus at day 28 (electrophysiological study) and the 
decreased freezing responses 30 min after intrahippocampal injection of 
philanthotoxin 433 (PhTX), a specific blocker of Ca2+-permeable GluR1 
containing AMPARs, at day 29, showed an influence of the traumatic event on 
the glutamatergic system. This increase in AMPAR-mEPSC amplitudes may 
result from an increased surface expression of AMPARs, especially GluR1-
containing AMPARs (O'Brien et al., 1998, Thoeringer et al., submitted). In 
addition, the reduced freezing responses 30 min after intrahippocampal 
injection of philanthotoxin 433 at day 29 post shock is in accordance with 
reduced contextual fear after pharmacological blockade of hippocampal AMPA 
and kainate receptors by NBQX and reduced contextual fear after inhibition of 
GluR1 synthesis (Thoeringer et al., submitted). Learning-induced trafficking and 
translation of this specific glutamate receptor subtype in the hippocampus have 
consistently been shown to be required for the consolidation of context (Matsuo 
et al., 2008; Mitsushima et al., 2011) or auditory fear memory (Thoeringer et al., 
2010). Noteworthy, treatment with philanthotoxin 433 attenuated contextual fear 
29 days, but not 3 days, after conditioning, thus substantiating that CA2+-
permebale GluR1 containing AMPARs play also a prominent role in the 
retention and/or expression of remote fear memories. 
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1.21 Pharmacological interventions of PTSD 
Every group of psychopharmacological agents has been claimed to be effective 
for the treatment of at least some aspects of the PTSD symptomatology. 
However, first-line therapies of PTSD in humans are selective serotonin 
reuptake inhibitors (SSRIs) including paroxetine and fluoxetine which reduce 
most of the PTSD symptoms (Connor et al., 1999; Van der Kolk, 2001; Tucker 
et al., 2001; Martenyi et al., 2002). However, the relapse rate after the cessation 
of treatment is high (Davidson, 1998). Therefore, this study investigated the 
effects of chronic treatment with fluoxetine on PTSD-like symptoms as well as 
CO activity as well as the relapse of behavioral symptoms after cessation. 
Concerning the different stage of PTSD, the incubation period and the 
maintenance, the treatment was started at different time points. The preventive 
treatment was started at the early aftermath of a trauma (day 1) and the 
therapeutic treatment after the incubation period, when PTSD-like symptoms 
already had occurred (day 28). Furthermore, the probability of a relapse after 
successful treatment with fluoxetine, testing 4 weeks after discontinuation the 
preventive as well as the therapeutic treatment was investigated. 
1.21.1 Predictive validity 
Preventive or therapeutic therapy with fluoxetine 
Preventive and therapeutic treatment with fluoxetine in shocked mice abolished 
PTSD-like symptoms in the hyperarousal symptomatology (Figure 16) and the 
generalized and contextual fear (Figure 17), which is in-line with the reduced 
avoidance behavior under chronic fluoxetine treatment shown by Pamplona and 
colleagues (Pamplona et al., 2011), reduced freezing response to conditioned 
stimuli by Siegmund and Wotjak (2007), and analog to humans studies (Connor 
et al., 1999; Martenyi, 2002). Furthermore, this study showed that under 
preventive treatment shocked, fluoxetine treated mice showed increased CO 
activity only in a few brain regions compared to control (vehicle treated) mice. 
The affected regions were as follows: the nucleus accumbens core (Acc C), the 
CA3 of the dorsal hippocampus, the ventral hippocampus (CA1 and CA3), and 
the striatum (CPu) (Figure 18), whereas under therapeutic treatment in every 
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analyzed brain regions the CO activity in shocked, fluoxetine treated mice were 
at the same level as controls (shocked, vehicle treated mice; Figure 19). These 
results were summarized in Table 9. Consequently, preventive but not 
therapeutic treatment prevented the development of chronic changes in CO 
activity. These findings are in consent with findings from Reinés and colleagues, 
who treated rats chronically with fluoxetine (10mg/kg i.p.) starting at d4 after 
exposure to the learned helplessness (LH) paradigm and found after 21 days of 
treatment decreased levels of escape latencies compared to vehicle treated rats 
(Reinés et al., 2007). In addition, in congenitally helpless rats chronic fluoxetine 
treatment increased the immobility in the forced-swim test to baseline level and 
the CO changes were in the predicted direction of metabolic normalization 
(Shumake et al., 2010). The direction of metabolic normalization was also 
observed in our mouse model where the CO activity after preventive treatment 
was at baseline level (level of non-shocked mice) in most of the analyzed 
regions. 
Therefore, the second working hypothesis “Chronic treatment with fluoxetine 
starting either right after the trauma (preventive treatment) or 28 days later 
(therapeutic treatment) reverses the PTSD-like symptoms.” can be accepted. 
Whereas the third hypothesis “Chronic treatment with fluoxetine starting either 
right after the trauma (preventive treatment) or 28 days later (therapeutic 
treatment) reverses the changes in CO activity.” was only partly confirmed. The 
preventive treatment with fluoxetine, but not the therapeutic, reversed the 
changes in CO activity. 
Wash-out after preventive and therapeutic therapy with fluoxetine 
Four weeks after discontinuation the fluoxetine treatment, the PTSD-like 
symptoms in the preventively treated group were still at baseline level (level of 
non-shocked mice; Figure 21 and 23), whereas in the therapeutically treated 
group, there was evidence of a relapse in hyperarousal symptomatology (Figure 
21) as well as in generalized and contextual fear responses (Figure 22). These 
findings are in-line with the findings of Reinés and colleagues, who investigate 
the changes in synaptic markers including synaptophysin (SYN) and 
postsynaptic density 95 (PSD-95), in an animal of depression (Reinés et al., 
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2007). Even starting the treatment at day 4, the behavioral symptoms and the 
changed levels of synaptic markers were present before starting the treatment 
and could inhibit via treatment with fluoxetine. However, after discontinuation 
the treatment, the behavioral symptoms as well as the changed levels of 
synaptic markers relapsed. Therefore, the improvement of symptoms as well as 
the recovered levels of synaptic and cytosceletal proteins under treatment are 
merely an inhibition but not a curative effect.  
Therefore the fourth and last working hypothesis “The discontinuation of 
treatment with fluoxetine after preventive or therapeutic treatment, leads to a 
relapse of PTSD-like symptoms.” is only partly true. After the therapeutic 
treatment with fluoxetine, which inhibited the PTSD-like symptoms, but did not 
affect the CO activity, a wash-out period of 4 weeks led to relapse of symptoms. 
However, after the preventive treatment, which prevented the increase of CO 
activity in most of the analyzed brain regions and therefore the development of 
PTSD-like symptoms, no evidence of relapse could be observed. 
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Conclusion 
Therapeutic treatment of PTSD, as commonly used in humans, is able to inhibit 
the PTSD-like symptoms in our animal model of PTSD, but is not able to cure 
the disease and therefore relapse of symptoms occurred after the end of 
therapy. However, preventive treatment of PTSD is able to avoid tonic activity 
changes in the neuronal activity and therefore avoid the development of PTSD-
like symptoms and as a result relapse of symptoms does not occur. 
For the first time it could be shown, that pharmacological intervention of PTSD 
is possible not only as a symptomatically and therefore short-dated therapy, but 
rather for a curative and long-term therapy of this disease. Taken together: 
 
The sooner the better! 
(At least if you are a mouse.) 
And: 
The reversal of CO activity changes may serve as a marker for the 
development of successful treatment!
Summary 
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Summary 
Posttraumatic stress disorder (PTSD) is characterized by exaggerated trauma-
related memories (contextual fear), increased avoidance of trauma-related 
cues, and hyperarousal. Pharmacotherapy of PTSD is still unsatisfactory, with 
SSRIs being the first choice drugs. However, as known for depressed patients, 
PTSD patients are prone for relapse of symptoms upon discontinuation of 
treatment. This urges for a refinement of therapeutic interventions and the 
identification of markers of treatment success. These issues were addressed in 
our mouse model of PTSD. In this model, mice are exposed to a brief, 
inescapable electric foot shock. Within 1 month after the trauma, they 
developed PTSD-like symptoms such as generalized contextual fear, 
generalized avoidance, and increased hyperarousal symptomatology. This time 
frame allows for pharmacological interventions during maturation of PTSD-like 
symptoms (i.e. preventive treatment) or at time points when the symptoms have 
fully developed (i.e. therapeutic treatment). The work presented in this thesis 
revealed the following key findings:  
 
(1) Fear incubation (i.e. simply the passage of time after trauma) was 
accompanied by highly selective changes in neuronal activity, as assessed by 
cytochrome c oxidase (CO) activity >1 month after trauma.  
 
(2) Chronic treatment with fluoxetine via drinking water starting either right after 
the trauma (preventive treatment) or 28 days later (therapeutic treatment) 
completely reversed the PTSD-like symptoms assessed during ongoing 
treatment 1 (preventive treatment) or 2 months (therapeutic treatment) after 
trauma.  
 
(3) Despite the similarities to PTSD-like symptoms, preventive treatment with 
fluoxetine abolished most of the trauma-related changes in CO activity, whereas 
those changes were maintained after therapeutic intervention.  
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(4) If fluoxetine was washed out after 1 month of treatment, PTSD-like 
symptoms remained absent following preventive treatment, but re-occurred 
after therapeutic treatment.  
 
In conclusion, these data suggest preventive treatment with fluoxetine starting 
in the early aftermath of a trauma as a successful intervention strategy for 
preventing the development of PTSD-like symptoms. In contrast, therapeutic 
treatment abolishes the expression of symptoms, without curative effects. 
Chronic changes in CO activity reflect traces of a trauma. They might serve as 
an indicator of PTSD relapse. 
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Perspectives 
In science, the fact that ‘You are at the end of a project.’ only means that you’re 
at the beginning of new ones.  
 
(1) Research of neuronal changes in patients with PTSD, a disorder which is 
long-lasting and ubiquitous, should investigate tonic (long-term) neuronal 
changes such cytochrome c oxidase (CO) or resting state activity like Lui and 
colleagues did in survivors of an earthquake (Lui et al., 2009). 
 
 (2) Research of the structural changes, e.g. increased spine intensity in the 
basolateral amygdaloid nucleus (BLA) which may facilitate symptoms of PTSD 
by enhancing connectivity and modulation for fear memory (Mitra et al., 2005) 
should be investigated in animals as well as in humans. 
 
(3) The CO seems to be a promising marker for successful treatment of PTSD, 
but can only been analyzed ex vivo. Nevertheless, the online monitoring of 
treatment success would be very helpful not only for PTSD, but a lot of other 
psychiatric disorders. Preliminary data already showed in an animal model for 
anxiety that CO activity was increased in the same regions as found with the 
MEMRI (manganese-enhanced MRI). Therefore, it would be interesting to 
measure shocked vs. non-shocked mice longitudinally up to 28 days after the 
traumatic event using MEMRI. If the activity is different between shocked and 
non-shocked mice, the investigation of activity changes after the preventive 
treatment with fluoxetine compared to vehicle in shocked mice must be 
obligatory. 
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Abbreviations  
 
AccC  accumbens nucleus core 
AccSh accumbens nucleus shell 
aCSF  artificial cerebrospinal fluid 
AMPA R α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AMY  amygdala 
AP5  D (-)-2-amino-5-phosphonopentanoic acid 
ASR  acoustic startle response 
BIM  (-)- bicuculline methiodide 
BLA  basolateral amygdaloid nucleus 
CA1  cornus ammonis 1 
CA3  cornus ammonis 3 
CC  cytochrome c 
CeA  central amygdaloid nucleus 
Cg1  cingulate cortex 
CO  cytochrome c oxidase 
CODA conditioned odor avoidance 
CPu  caudate putamen 
DAB  2,6-Diacetylpyridine 
DG  dentate gyrus 
dHPC  dorsal hippocampus 
GABAAR γ-aminobutyric acid receptor A 
GluR1  subunit of AMPAR 
IL  infralimbic cortex 
Abbreviations 
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INT  intensity 
K+P-buffer potassium phosphate buffer  
LA  lateral amygdaloid nucleus 
NBQX  2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione 
LH  lateral hypothalamic area 
LHb  lateral habenular nucleus 
M  molar concentration 
MHb  medial habenular nucleus 
mEPSC miniature excitatory post-synaptic current 
mIPSC miniature inhibitory post-synaptic current 
mPFC  medial prefrontal cortex 
Na+P-buffer sodium phosphate buffer  
OD  optical density 
PAG  periaqueductal gray 
PF  parafascicular thalamic nucleus 
PFA  paraformaldehyde 
PhTX  philanthotoxin 433 
PrL  prelimbic cortex 
PTSD  post traumatic stress disorder 
PVA  paraventricular thalamic nucleus 
ROI  region of interest 
RT  room temperatur 
SN  substancia nigra 
TTX  tetrodotoxin 
vHPC  ventral hippocampus 
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Chemicals 
 
AP5     Ascent Scientific 
BIM     Tocris Biosciences 
CaCl2     Merck 
CC (C2506)     Sigma-Aldrich cytochrome c 
C6H7NaO6     Merck   sodium ascorbate 
DAB (A1827)   Sigma-Aldrich 
isopentyl acetate (“banana”) Sigma-Aldrich 
NaCl      Merck 
NaHCO3    Merck 
NaH2PO4 H2O   Merck 
Na2HPO4 2H2O   Merck 
NBQX     Ascent Scientific 
(NH4)2Ni(SO4)2 · 6H2O (A1827) Sigma-Aldrich ammonium nickel sulfate 
KCl     Merck 
K2- EDTA    Merck 
K3Fe(CN)6    Sigma-Aldrich potassium ferricyanide 
KH2PO4    Merck 
MgSO4     Merck 
PhTX      Sigma-Aldrich 
Tris-HCl    Sigma-Aldrich 
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